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Abstract

Nerve growth factor regulates Na+ transport in human
airway epithelial cells
Michael Shimko
Nerve growth factor (NGF) was discovered for its ability to enhance nerve
growth, but recent evidence suggests there is a correlation between elevated NGF levels
in the lung and airway diseases, including lung inflammatory diseases and respiratory
virus infections. NGF can be produced and act upon both structural and non-structural
cells of the airways, and overexpression of NGF causes morphological and physiological
changes in the airways, such as an increased innervation resulting in a neuronal
remodeling of the lung, airway smooth muscle thickening, increased vascularization,
airway hyperreactivity to capsaicin, and subepithelial thickening. Although work has
been conducted to investigate NGFs effects on ion transport in non-airway cells, such as
PC12, MTAL, and HEK-293 cells, no information is available regarding the effect NGF
has on ion transport of airway epithelial cells. To investigate whether NGF can affect
epithelial ion transport, a well-differentiated human primary cultured epithelial cell
model was developed. The ability for these cells to differentiate into epithelial cells,
which represent in situ epithelial morphology, was confirmed using several imaging
techniques. Cells were placed in Ussing chambers to obtain transepithelial voltage (Vt, 7.1 ± 3.4 mV), short-circuit current (Isc, 5.9 ± 1.0 µA), and transepithelial resistance (Rt,
750 Ω∙cm2), and to measure responses to ion transport inhibitors. Apical and basolateral

NGF concentration-response curves were generated, but NGF only evoked bioelectric
responses apically with the maximum response occurring at 1 ng/ml. To investigate the
ionic basis for the bioelectric responses to NGF, responses to known ion transport
inhibitors were generated in the absence or presence of 1 ng/ml NGF. The addition of 1
ng/ml of NGF to the apical membrane decreased Isc by 5.3 %. Amiloride (apical, 3.5×10-5
M), which inhibits Na+ transport, decreased Isc by 55.3 % in the absence of NGF, but this
response was reduced (41.6 %; p = 0.0127) in the presence of 1 ng/ml NGF, which
indicated NGF was affecting amiloride-sensitive Na+ transport. There were no
differences in response to NPPB or ouabain, indicating NGF did not have an affect on Cl–
transport or the Na+/K+-ATPase. To investigate if the trkA receptor was responsible for
mediating the NGF-induced reduction in Na+ transport, the non-specific tyrosine kinase
inhibitor, K-252a (10 nM, apical), was used. K-252a reduced the NGF bioelectric
response as well as attenuated the NGF-induced reduction in Na+ transport. The trkA
receptor activates the Erk 1/2 signaling pathway, which has been shown to phosphorylate
ENaC and reduce Na+ transport by channel degradation through a NEDD4-mediated
ubiquitin pathway. To investigate if NGF is activating the Erk 1/2 signaling pathway
downstream of trkA, the specific Erk 1/2 inhibitor, PD-98059 (30 µM, apical and
basolateral), was used. PD-98059 reduced the NGF-induced bioelectric response as well
as attenuated the NGF-induced reduction in Na+ transport. Protein analysis using western
blot techniques confirmed NGF-mediated reduction in Na+ transport was a result of Erk
1/2 activation and ENaC phosphorylation.

To investigate if incubation with NGF can elicit changes in ion transport, cells
were incubated with NGF for 24 or 48 h prior to placing to cells into Ussing chambers.
Cells exposed to NGF for either 24 or 48 h did not demonstrate changes in ion transport
as compared to control cells, indicating NGF did not have a genomic effect on ion
transporter subunit expression. These results also suggest that the rapid reduction in
amiloride-sensitive Na+ transport is a transient reduction. To determine if this lack of
response was a result of a decreased concentration of NGF during the incubation period,
a NGF-specific ELISA assay was used. Cells internalized or metabolized 94% of initial
concentration of NGF applied within 5 min, as inserts without cells did not demonstrate a
reduction in NGF concentration.
The findings discussed in this dissertation indicate that NGF causes a transient
and non-genomic reduction in Na+ transport in epithelium through a trkA-Erk1/2mediated signaling pathway, resulting in the internalization and degradation of ENaC.
This reduction in Na+ transport would result in the hydration of the airway surface liquid.
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Chapter 1
Introduction and Discovery of NGF
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Introduction
Nerve growth factor (NGF), discovered by Rita Levi-Montalcini in the late
1950’s, was the first member of the neurotrophin family. Several other neurotrophins
have since been discovered, including brain-derived neurotrophic factor (BDNF),
neurotrophic factor 3 (NT-3), and neurotrophic factor 4/5 (NT-4/5).
Levi-Montalcini was born in Turin, Italy on April 9, 1909. She graduated from
Turin medical school in 1936 with a degree in Medicine and Surgery before spending
three years in a specialized neurology and psychiatry program at the same university
working with Dr. Giuseppi Levi. In 1938 Benito Mussolini published the Manifesto of
Race which prevented Levi-Montalcini from working at the university. Determined to
continue practicing her new passion of research, Levi-Montalcini set up a makeshift
laboratory in her countryside home where she confirmed and expanded upon the effects
of limb removal on the development of the nervous system, which was previously
reported by Viktor Hamburger. After Hamburger learned about Levi-Montalcini’s work,
he offered her a one year position in his laboratory in 1946. Levi-Montalcini moved to
Washington University in St. Louis to work with Hamburger. In Hamburger’s laboratory,
Levi-Montalcini made several important discoveries which eventually lead to the
discovery of NGF. The exciting discoveries which took place extended Levi-Montalcini’s
one year rotation to her spending thirty years at the Washington University (24, 54).
Although Levi-Montalcini and Hamburger designed several very important
experiments to identify the ability of mouse sarcoma tumors to increase the size of the
chicks embryo sensory ganglia, their abilities to identify the compound responsible for
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this enhanced nerve growth was lacking. Stanley Cohen was born in Brooklyn in 1922,
attended Brooklyn College where he majored in biology and chemistry, and obtained his
masters at Oberlin College and Ph.D. in biochemistry at the University of Michigan in
1948. In 1952 Cohen moved to Washington University to work in the radiology
department. Cohen and Levi-Montalcini crossed paths at the university. Needing a
biochemist, Hamburger secured funding to allow Cohen to join his team and aid in the
identification and characterization of the nerve growth factor which was being released
by the sarcoma tumors to increase the size of the chick embryo sensory ganglia. Stanley,
Levi-Montalcini, and Hamburger published their first joint paper in 1954 titled “A Nerve
Growth-Stimulating Factor Isolated from Sarcomas 37 and 180” (22). This was the last
publication to include Hamburger as an author, as Hamburger felt he could not contribute
to the content of the experiments with his lack of knowledge in the field of biochemistry.
Levi-Montalcini and Cohen went on to publish numerous publications dealing
with the newly discovered nerve growth agent, later termed nerve growth factor (NGF).
Their efforts to identify the protein that caused enhanced nerve growth earned LeviMontalcini and Cohen the Noble Prize in Medicine or Physiology in 1986 (24). LeviMontalcini founded and headed the European Brain Research Institute (EBRI) located in
Rome, Italy. Levi-Montalcini never retired, and was the longest living Noble Prize
winner to date. She used NGF eye drops daily, and believed they gave her energy and
kept her brain function properly. Levi-Montalcini passed away on December 30, 2012 at
the age of 103 (16).
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Discovery of NGF
The discovery of NGF came after an experimental observation made by Bueker et
al. in 1947 (15). Using a technique involving transplanting mouse tumors intraembryonically in chick embryos, Bueker found that the transplanted tumor, sarcoma 180,
was highly invaded by the host sensory nerve fibers. The ganglia, located on the same
side as the tumor, were also considerably larger (14, 15). Expanding on this work, LeviMontalcini et al. transplanted both sarcomas 37 and 180 intra-embryonically and
examined nerve growth during the entire developmental period of the chick embryo. She
discovered that both sarcomas 37 and 180 caused a 600 % increase in the size of the
sympathetic ganglia adjacent to the tumor (48, 53). The increased nerve volume was
attributed to increased cell number, increased cell size, and accelerated differentiation
(48). From these results, it was concluded that the sarcoma 37 and 180 tumor cells
produced and released a nerve growth stimulating agent that was specific for sensory
cells and sympathetic ganglia (48).
After discovering that sarcomas 37 and 180 had effects on nerve growth, LeviMontalcini et al. began to isolate the agent responsible for the increase in nerve growth.
She cultured chick embryo sensory ganglia using a hanging drop method in which the
media used to grow the ganglia contained either homogenates of sarcomas 37 or 180
tumors grown in the body wall of chick-embryos or saline. Ganglia cultured in media
containing sarcoma homogenates had increased neuronal outgrowth compared to saline
controls. Sarcomas 37 and 180 tumors, which were grown in a mouse host, did not have a
growth effect on ganglia (22). Sarcoma 37 and 180 tumors, which were grown in the
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body wall of a chick embryo, were homogenized, separated through differential
centrifugation, and each component (whole homogenate, nuclei, mitochondria,
microsomes, and supernatant) was added to the culture medium used to culture chick
embryo sensory ganglia. Of the cellular components obtained during differential
centrifugation, the microsomal fraction resulted in the highest degree of neuronal
outgrowth. Further investigation was conducted by precipitating out from the microsomes
highly polymerized nucleic acids and nucleoproteins using streptomycin. After
precipitation, the supernatant had no effect on chick embryo sensory ganglia growth, but
the re-suspended fraction containing the polymerized acids and nucleoproteins resulted in
an increased nerve growth. The growth factor in the re-suspended fraction was found to
be heat sensitive and nondialyzable.
The agent which caused enhanced nerve growth was also found to be a diffusible
agent. This was discovered using in vitro co-cultures of sarcoma 37 or 180 and chick
embryo sensory ganglia located in close proximity to each other (55). Nerve fiber
outgrowth, in this in vitro experimental design, started at 12 h, peaked at 24 - 48 h, and
then regressed. The neuronal outgrowth was not directed towards the tumor, but, rather,
equally in all directions.
During the process of trying to identify the agent which was responsible for the
increased nerve growth, snake venom was used as a source of a phosphodiesterase. It was
found that treatment of sarcoma homogenates with snake venom enhanced its effect on
nerve growth (20). The increased activity after treatment suggested the venom also
contained an agent which caused increased nerve growth, and was later determined to be
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3,000 - 6,000 times as active as the sarcoma homogenates. The effects of snake venom on
nerve growth could be blocked with anti-snake serum, heating, and acid treatment. The
agent in snake venom was also determined to be nondialyzable and proteinaceous. Both
sarcoma lysate and snake venom had similar effects on nerve growth and function in
chick embryos (52). Cohen demonstrated that venom from different snake species had
different potencies in eliciting nerve growth, with the most potent venom being from
Vipera russelli and Vipera aspis. Using ultracentrifugation, Cohen detected a protein in
the snake venom with a mass of 2.2 S and an absorbance spectrum 280/260 ratio of 1.3
(18). After purifying the venom, Cohen concluded the agent responsible for the enhanced
nerve growth was a protein after incubating the purified venom with proteolytic enzymes
and observing a reduction in activity. Venom incubated with RNase or DNase retained
the ability to enhance nerve growth (18).
The results obtained so far demonstrated the ability of two unrelated sources,
mouse sarcoma tumors and snake venom, to cause an increased level of growth in chick
sensor nerves and sympathetic ganglia. Since the snake venom, which is produced in
modified salivary glands in the snake, had a greater effect on nerve growth than the
sarcoma homogenate, Levi-Montalcini et al. investigated whether the mouse salivary
glands produced a similar effect on nerve growth using both in vitro and in vivo
techniques. She found that homogenized mouse salivary glands, which proved to be
much more potent than sarcoma homogenates and snake venom, produced similar results
on mouse nerve growth and differentiation (51). Levi-Montalcini et al. demonstrated that
the salivary factor could increase the size of ganglia isolated from human aborted fetuses,
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rodents and birds. In vivo, newborn mice, injected daily after birth with purified salivary
gland extract, had twice as many cells located in their superior cervical ganglia as
compared to controls after nineteen days, which was due to both hypertrophy and
hyperplasia of the cells. When adult mice were injected daily with the purified salivary
factor, their ganglia doubled in size, but this doubling was due to cellular hypertrophy
only (51).
Levi-Montalcini and Cohen detected that the purified mouse salivary glands
produced a very potent factor which caused nerve growth in several different species. The
salivary glands were a very accessible source of this growth factor. The salivary gland
homogenates were purified by Cohen through a series of precipitation and centrifugation
steps prior to separating the material through a cellulose column (50). The purified
salivary gland extract required 0.015 µg/ml of purified protein to generate a halo effect
on cultured sensory ganglia, compared to 1.5 µg/ml of salivary gland homogenate and
0.15 µg/ml of purified snake venom. So far, all of the evidence from the purification
steps suggested the compound responsible for nerve growth was a protein.
An antibody to the growth factor was developed to determine if the effect of the
purified salivary gland extract could be inhibited. Rabbits were injected with the purified
salivary gland extract along with Freund’s adjuvant. Rabbit serum, when added to in vitro
hanging drop assays to assess ganglia growth, blocked the responses to purified salivary
glands and snake venom, but serum from non-treated rabbits did not (19). When this
rabbit anti-serum was injected into both newborn and adult mice, the anti-serum caused a
93 % reduction in the cell population of the superior cervical ganglion, but animals
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injected with the control serum were unaffected (49, 51). The ability of the anti-serum to
reduce the number of cells in the ganglia was confirmed in several other species,
including rats, rabbits, and cats.
The identification of the molecular characteristics of NGF could be investigated
in more depth with the readily available and highly potent source from salivary glands.
Bueker et al., improving on Cohen’s isolation and purification methods, performed
electrophoresis on the purified protein, and assayed each band for its biological ability to
induce neuronal outgrowth of chick embryo sensory ganglia (74). The results indicated
that two proteins, only in combination with each other, produced an increased level of
neuronal outgrowth. Bueker determined the molecular weight of the two proteins to be
8.6 and 4.3 kDa. The 280/260 ultraviolet-absorption ratio, for the protein with the
molecular weight of 8.6 kDa, was 1:78. The protein with a molecular weight of 4.3 kDa
was negative to ultraviolet-absorption. This absorption ratio was slightly different from
those obtained from earlier in the mouse sarcoma (1:25) (21), snake venom (1:30) (18),
and mouse salivary gland (1:53) (19). The estimated molecular weights were also slightly
different than the previously reported 20 kDa from the snake venom (18) and 40 kDa
from the salivary gland (19). Bueker, by hydrolyzing the protein using HCl and heat,
identified the amino acids which composed the 8.6 and 4.3 kDa proteins, as well as
determined the C and N terminal amino acid residues (74).
Differences in the isolation and purification processes could be the reason why
different investigators obtained different results in the identification of the protein
responsible for increasing nerve growth. Varon, using gel filtration, identified the parent
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protein which causes enhanced nerve growth as a large protein with a mass of 140 kDa
(85). This large molecule is then split into three separate subunits, α, β, and γ, with the βsubunit containing the nerve growth properties. Other reports indicated the activity of the
β-subunit can be enhanced in the presence of the α- and γ-subunits (86). The β-subunit
has a sucrose density of 2.5 S.
Although these initial reports provided an initial identification of the protein, it
was not until 1971 when Angeletti determined the sequence of the active component of
the protein responsible for the enhanced nerve growth (1, 2). Following up on the
previous work of Bocchini, who published the first predicted amino acid sequence of the
protein in 1970 (12), and Varon, who determined that NGF was composed of three
subunits, Angeletti determined the protein composition and amino acid sequence through
a series of tryptic, chymotryptic, thermolytic, and peptic digestions of the 2.5 S β-NGF.
Angeletti’s analysis revealed that the primary NGF protein contained a homodimer of βNGF with an estimated weight of 26.5 kDa. Each subunit of β-NGF contained 118 amino
acids and has an estimated molecular weight of 13.3 kDa, an isoelectric point of 9.3, and
three disulfide bonds (1).
The identification of the amino acid sequence allowed researchers to investigate
the secondary structure of the NGF protein. Argos suggested initially, based on the amino
acid sequence, that NGF existed in an approximately 53 % helix confirmation (4). This
was later found to be inaccurate, as Williams et al., using Raman spectroscopy, identified
that NGF was mostly a β-sheet, with little to no helix structure (91). The reports that
NGF existed in mostly a β-sheet were confirmed when McDonald et al. published the
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first crystal structure of NGF, and determined NGF to have three anti-parallel pairs of βsheets with four loop regions to give a very flat surface (60). McDonald also reported that
NGF’s structure measured 60 × 25 × 15 Å with a surface area of 7,229 Å2.

β-NGF chromosomal gene location
NGF is secreted as a pre-pro-NGF protein. This pre-pro-protein consists of α-, β-,
and γ-subunits with a molecular weight of 130 kDa or 7 S. The initial amino acid
sequence for NGF was determined by Angeletti using purified NGF from mouse salivary
gland extract (2). Determining the protein structure of NGF allowed researchers to
determine the β-NGF’s nucleotide sequence. Ullrich et al. utilizing a cDNA cloning
approach, found the nucleotide sequence for β-NGF to be highly homologous between
the mouse and human and contain a 87 % similarity (81, 82). Scott et al., using NGF
mRNA from the mouse submaxillary gland, generated a cDNA probe corresponding to
the predicted NGF amino acid sequence (76). Zable et al., using this NGF cDNA clone,
identified the chromosomal location of NGF in both the mouse and human, as Axel
demonstrated the two species have a high level of gene homology. In the mouse, NGF is
located on chromosome 3, and in humans NGF is located on chromosome 1p21-22 (26,
94).

Discovery of other members of the neurotrophin family
Brain-derived neurotrophic factor
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Brain-derived neurotrophic factor (BDNF), discovered by Barde et al. in 1982,
was the second member of the neurotrophin family to be discovered (8). The initial
observation that a second growth factor, other than NGF, could be secreted by cells to
promote the growth and survival of neurons occurred in 1978 (9). Cell culture media,
when conditioned by C-6 glioma cells, demonstrated the ability to cause an increase in
chick embryo sensory ganglia outgrowth similar to that of NGF. This increase in
neuronal outgrowth could not be blocked by the addition of an NGF-antibody, and
suggested the glioma cells secreted a substance other than NGF to cause enhanced
neuronal outgrowth (9). Using pig brain to isolate and purify the new growth factor
revealed the presence of a monomer with an initial estimated molecular weight of 12.3
kDa. This molecule was determined, again, to not be NGF by the inability of NGFantibodies to block the biological activity of the growth factor as well as the inability to
detect NGF in the purified protein sample. Further investigation into the structure, amino
acid homology (50 %), and amino acid length (NGF 118 base pairs, BDNF 112 base
pairs) revealed BDNF to be very similar to NGF. They each contain three disulfide
bridges which contribute to their biological activity, and they have a similar tertiary
structure (33, 47). Although there is a high level of homology between NGF and BDNF,
their genomic locations vary, with NGF located in humans on chromosome 1 p21-22 and
in mice on chromosome 3 11 (26, 94), and BDNF located in the human on the human
chromosome 11 p13 and on chromosome 2 in the mouse (57).

Neurotrophin-3
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The third member of the neurotrophin family, neurotrophin-3 (NT-3), was
discovered by Hohn et al. in 1990. Recognizing that the work done by Leibrock et al. in
1989 demonstrated how similar NGF and BDNF were in structure and function, Hohn
proposed that because of the similarities these two proteins had belong to a similar class.
To investigate if there were other members of this family, he compared the sequences of
NGF and BDNF and found two stretches of six amino acids were conserved in each
protein. Generating oligonucleotide primers based on the two sequences, Hohn used
polymerase chain reaction (PCR) to amplify a mouse genomic template. The result from
this experiment was the discovery of a 119 amino acid long protein, termed NT-3 (33).
Again, this neurotrophin shares similar features with NGF and BDNF. The amino acid
sequences between the three proteins are 50% conserved, which included the three
disulfide bonds formed by six highly conserved cysteine residues. There were also four
variable regions identified in NGF, BDNF, and NT-3 that consist of seven to eleven
amino acids responsible for some of their specific characteristics (33). There is also a
difference in the calculated isoelectric points for each of the proteins compared to NGF
(11.4), BDNF (5.1), and NT-3 (9.0) (7). NT-3 is located in humans on chromosome
12p13 and in the mouse on chromosome 6 (67).

Neurotrophin-4/5
The last member of the neurotrophin was discovered by Hallbook et al. in and
Berkemeier et al. in 1991 (10, 29). Because the discovery of these proteins occurred at
relatively the same time, each researcher gave their discovered protein a unique name.
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Hallbook, who published his findings first, termed the new protein neurotrophin-4, while
Berkemeier, who acknowledges Hallbook’s work in his own findings, believed he
identified a different neurotrophin and termed it neurotrophin-5. Berkemeier does
acknowledge that the only difference in NT-4 and NT-5 is the tissue distribution, but this
would later result in the in the neurotrophin being referred to as neurotrophin-4/5 (NT4/5). Again, these proteins were discovered utilizing the known structures of the
previously discovered neurotrophins, and oligonucleotide primers were constructed and
used in PCR amplification of various species to study the distribution of these
neurotrophins. Data generated from viper and Xenopus DNA fragments revealed the
presence of a new sequence which was then confirmed in a host of other species,
including humans (29, 35). The new sequence was highly conserved in comparison to the
other three neurotrophins with a 50-60 % amino acid homology, and it also contained the
three characteristic cysteine disulfide bonds. The NT-4/5 protein is also secreted as a
larger pro-protein, and then cleaved into the 123 amino acid long mature active protein
which has been shown to enhanced outgrowth of dorsal root ganglia (29). In humans, the
gene for NT-4/5 is located on chromosome 19 q13.3 (35).

Neurotrophin receptor family
Introduction
The four members of the neurotrophin family, NGF, BDNF, NT-3, and NT-4/5,
are secreted proteins which elicit their effects on their target cells through a high affinity
tyrosine kinase named tropomyosin-related kinase receptor, referred to as trk, and a low
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affinity tumor necrosis factor (TNF) receptor, referred to as p75NTR. There have been
three members of the trk family discovered, trkA, trkB, and trkC, and all of the members
of the neurotrophin family bind specifically to their corresponding trk receptor. All
members of the neurotrophin family bind nonspecifically to p75NTR. The discovery of
these receptors came long after the initial discovery of NGF, but since their discovery a
lot of work has been done to characterize their function and intracellular signaling
pathways triggered by neurotrophins.

Discovery of the neurotrophin receptor(s)
The initial publication by Bueker et al. in 1947 (15) reported that a mouse
sarcoma tumor produced an agent that increased nerve growth. This was followed by the
discovery of NGF in the late 1950’s by Levi-Montalcini et al. with the final protein
sequence determined in 1971 by Angeletti et al. (1). Once the protein sequence was
determined, it allowed researchers to start to identify the other members of the
neurotrophin family and the receptors responsible for regulating their effects on the cell.
The first receptor studies were conducted by Banerjee et al. (6). Using 125I-labeled NGF
and rabbit superior cervical ganglia, the NGF receptor was found to reside in the
membrane fraction of ganglia homogenates. This binding was inhibited by increasing
levels of nonradioactive NGF but not by other hormones, including epidermal growth
factor (EGF), proinsulin, and insulin, which indicated the receptor was specific for NGF.
The interaction between NGF and the NGF receptor is also dependent on the presence of
Ca2+, with maximal NGF binding occurring in the presence of 5 mM Ca2+ (5). Binding
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was also determined to be saturable at 0.2 nM NGF as reported by Banerjee et al., or 3050 ng/ml NGF as reported by Herrup et al. (6, 32). Frazier et al. demonstrated that
peripheral neurons and organs contained receptors specific for NGF on their cell surfaces
(27, 28). The binding kinetic data generated from these initial experiments suggested the
existence of only one membrane bound receptor for NGF.
Later work would support the idea that two different receptors for NGF exist (46,
73, 79, 80). Sutter et al., using 8-day old chick sensory ganglia, demonstrated two
saturable binding sites for radiolabeled 125I-NGF with unique binding affinities
representing a high affinity receptor with a dissociation constant (Kd) value of 2.3 × 10-11
and a low affinity receptor with a Kd of 1.7 × 10-9 (80).

trkA
Martin-Zanca et al. published the initial molecular characterization of trkA in
1986, which was a result of an investigation of an up-regulated proto-oncogene isolated
from a colon carcinoma biopsy (58, 59). The trkA protein was composed of 790 amino
acids and determined to have a molecular weight of 110 kDa, and, in humans, the gene
which encodes trkA resides on chromosome 1q21-11 (88). The trkA protein undergoes a
series of glycosylation steps in which it is predicted to be glycosylated while in the
endoplasmic reticulum and then again when it is transported to the cell membrane. Only
the glycosylated mature protein, with a molecular weight of 140 kDa, is incorporated into
the plasma membrane. The protein also contains an intracellular tyrosine kinase domain
which shares high homology with other tyrosine kinase receptors (59). The extracellular
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domain contains 24 cysteine residues, similar to that of other cell surface receptors, such
as the EGF receptor, EGFR (37).

trkA neurotrophin binding
Kaplan et al. first reported that NGF specifically activates trkA receptors in PC12
cells (40). The activation and phosphorylation of the trkA receptor was demonstrated to
be specific for NGF, as other factors which stimulate other members of the tyrosine
kinase family did not activate the trkA receptor. The addition of NGF to PC12 cells
resulted in activation of the trkA receptor within 1 min, with a maximum activation
occurring at 5 min post-exposure. This activation also occurred at physiologic
concentrations of NGF, and demonstrated a half-maximum activation in the presence of
0.1 ng/ml NGF (39, 40). Klein et al. demonstrated that NGF bound specifically to the
trkA receptor and not to the other members of the trk family (42). Although the work
conducted by Sutter et al. demonstrated the presence of two different receptors with
notably different binding affinities, Meakin et al. was the first to term the trkA receptor
the high-affinity receptor (61, 62). This high affinity receptor, trkA, binds NGF for a
longer duration than the low affinity receptor, p75NTR (84).
Once NGF binds to the trkA receptor, the NGF-trkA complex is rapidly
internalized (72). Because topology is conserved when the NGF-trkA complex is
internalized into vesicles, the activated tyrosines, located on the intracellular region of the
trkA receptor, continue to activate intracellular signaling cascades, and the trafficking of
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the intracellular vesicle determines the intracellular signaling pathway to be activated
(34).

trkB
The second member of the trk family, trkB, was identified by Klein et al. in 1989
(44, 63). Using probes to investigate the distribution of RNA for trk in different cell
types, Klein obtained different results from those of Martin-Zanca, who published the
first reports of trkA. The differences in the results lead to the generation of trk-specific
DNA probes, and revealed the presence of a gene which was related to but distinct from
the trkA receptor initially discovered. This new trk receptor was termed trkB. trkB was
shown to have high levels of homology with that of trkA, with 57 % homology in the
extracellular domain and 88 % homology in the catalytic domain. The glycosylated
molecular weight of trkB (145 kDa) is very similar to that of trkA (140 kDa).

trkB neurotrophin binding
Cordon-Cardo et al. co-transfected NIH 3T3 cells with a plasmid containing the
NGF gene and a plasmid containing the trkA gene, and demonstrated that NGF, acting
through the trkA receptor, had a mitogenic effect on the cells and also caused the cells to
become morphologically transformed (23). Kline et al. used this technique to investigate
the binding of neurotrophins to the trkB receptor, and co-transfected NIH 3T3 cells with
a plasmid containing trkB and a plasmid containing either NGF, BDNF, or NT3 (43). The
results demonstrated that cells transfected with NGF and trkB did not cause any level of
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cellular transformation, but cells containing trkB with either BDNF or NT-3 had a high
level of transforming activity. Later, NT-4/5 was also demonstrated to bind and elicit its
signaling effects on the cell through trkB (92).

trkC
The last member of the trk family, trkC was identified and characterized by
Lamballe et al. (45). This receptor was discovered through screening porcine brain DNA
with probes which were generated using the catalytic domain of trkA. The cDNA which
hybridized with the probes used to screen the porcine brain did not hybridize with probes
corresponding to regions of trkA or trkB cDNA, indicating that this was a different trk
receptor, which they names trkC. The protein sequence of trkC is very similar and shares
a high level of homology with that of trkA, 67 %, and trkB, 68 %, with the extracellular
domain having a 54 % homology with trkA and 53 % homology with trkB. The external
domain of trkC also contains several of the highly conserved cysteine residues. The
catalytic domain of trkC shares an 87 % homology with trkA and 88 % homology with
trkB. The glycosylated trkC protein had an identical molecular weight as trkB, 145 kDa
(45).

trkC neurotrophin binding
Lamballe et al. also investigated the neurotrophins which bind to trkC (45). Using
NIH 3T3 cells which were transfected with a plasmid containing the trkC gene, cells
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were incubated with 125I-labeled NGF, BDNF, or NT-3. Only NT-3 demonstrated binding
to the cells, which was inhibited by non-labeled NT-3.

p75NTR
The possibility that NGF had multiple receptors was initially suggested when
Sutter et al. (80) demonstrated that NGF bound to two sites, which had binding affinities
that differed by 2 log-orders. Vale et al. demonstrated that NGFs association with the low
affinity receptor, p75NTR, was significantly shorter than that of the high affinity receptor,
trkA, and thus, at the time, termed it the fast NGF receptor (NGFR) (80, 84). Radeke et
al., by generating a probe specific for the NGFR receptor, was able to generate
complementary DNA to the NGFR allowing the molecular sequence and structure of
p75NTR to be determined (69). The mature p75NTR receptor is composed of 396 aminoacid residues and has a molecular weight of 42.5 kDa. The receptors extracellular domain
is composed of 222 amino-acids and contains several repeating cysteine regions similar
to that of trkA, a single transmembrane domain composed of 24 amino-acid residues, and
a intracellular domain containing 151 amino-acid residues.

p75NTR neurotrophin binding and intracellular signaling pathways
Unlike the trk receptors, trkA, trkB, and trkC, which demonstrate neurotrophin
binding specificity, the p75NTR binds non-specifically to all members of the neurotrophin
family with almost equal affinity but different binding kinetics (13). Although the trk
receptors activate signaling pathways responsible for growth, differentiation, and
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survival, there is a large body of work that supports the view that p75NTR is responsible
for enhancing trk activation. This was first suggested when Choa demonstrated that
neurotrophin binding was increased in cells expressing both trk and p75NTR, and this
binding was reduced in the presence of the trk receptor only, suggesting that cooperation
existed between the two receptors (17). This was also demonstrated by Verdi et al. using
sympathoadrenal cells containing trkA alone or trkA with p75NTR, and cells which
contained both receptors had an 8-fold higher activation in trkA activation as compared
to cells which contained only trkA (87).
The crystal structure for p75NTR bound to NGF reveals a 2:1 NGF:p75NTR
complex, which is different from the reported 2:2 ratio of NGF:trkA binding (31, 90).
This binding ratio suggests that the homodimer of β-NGF binds with one p75NTR
receptor. NGF binds in in a parallel fashion with two sites on the p75NTR receptor, termed
site I and site II. The first binding site, site I, is near the end of the extracellular domain of
the receptor located near the cysteine rich domains 1 and 2, and the second binding site,
site II, is located in the region closest to the transmembrane domain on the extracellular
domain near the cysteine-rich domains 3 and 4. The high level of conserved amino acid
regions between all of the neurotrophins suggests these regions are highly conserved.
Although p75NTR binds to one of the NGF dimers, the binding results in structural
changes in the second NGF dimer. Because p75NTR is a rigid receptor, structural changes
in NGF, which occur once the homodimer is bound, prevents binding to a second p75NTR
receptor. The availability of a second NGF dimer could explain the notion that p75NTR
affects trkA binding to NGF, and this complex would allow the trimolecule of NGF,
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trkA, and p75NTR to form. This trimolecule binding could explain the complex signaling
pathways documented which result after NGF binding.
The activation of the p75NTR by neurotrophins can result in the activation of either
prosurvival intracellular signaling pathways, such as NF-κB and Akt, proapoptotic
intracellular signaling pathways, including Jun, Jnk, sphingolipid turnover, neuropeptide
receptor-interacting MAGE homolog (NRAGE) and p75NTR-associated nerve death
executor (NADE), or activate signaling pathways responsible for cellular growth and
motility, including the Rac and Rho pathways (30, 38, 66, 70, 71, 89, 93). The activation
of the p75NTR pro-apoptotic signaling pathways has been shown to be regulated by trk
receptor signaling, specifically trk-mediated activation of Raf and Akt, to promote
neurotrophic prosurvival and pro-differentiation effects (64). Upon NGF binding the
NGF-p75NGF complex is not internalized as occurs when NGF binds to trkA (11, 77).

trk structure and intracellular signaling pathways
The extracellular domain of the trk receptor family, trkA, trkB, and trkC, is
responsible for the binding its corresponding neurotrophin to result in the activation of
the receptor and, therefore, activates several intracellular signaling cascades which allows
cells to respond to their extracellular environment. The trk receptors extracellular domain
is very unique in comparison to other members of the tyrosine kinase family of receptors,
and is composed of two cysteine-rich domains separated by a region of three leucine-rich
regions followed by two C2-type immunoglobulin (Ig-C2)-like domains before a single
transmembrane domain and an intracellular domain, which is structurally similar to other
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members of the receptor tyrosine kinase family (34, 75). As mentioned above, the trk
family receptors display specific binding to their respective neurotrophins, with NGF
specifically binding and activating the trkA receptor. This specificity results primarily
from differences in the major neurotrophin binding domain 5, Ig-C2 (68, 83), but can also
be mediated partially by the cysteine-rich domains (3). The trkA immunoglobulin domain
5, alone, has been shown to bind to NGF with similar binding affinities to that of the
native receptor (90)
Jing et al. demonstrated that once NGF binds to trkA, the trkA receptor forms a
stable dimer (36). When the kinase domains are brought into close proximity to one
another upon dimerization, the contralateral kinase domain auto-phosphorylates tyrosines
located at positions Y670, Y674, and Y675, which then leads to the auto-phosphorylation
of three tyrosines on the outside kinase domain at positions Y490, Y751, Y785 (40, 65,
78). The negatively charged phosphorylated tyrosines on the outside region of the kinase
domain generate docking sites for adaptor proteins containing basic residues, such as
PTB and SH2 domains (25). Phosphorylated Y490 recruitments and binds Shc and
fibroblast growth factor receptor substrate 2 (Frs2) resulting to activate the downstream
signaling pathways Ras-Raf-Erk and PI3-kinase-Akt. Phosphorylated Y785 activates the
PLC-γ and the PKC pathways (41, 56, 78). The activation of these pathways results
primarily in cell survival and differentiation.
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NGF and Lung Disease
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Introduction
NGF was discovered for its ability to enhance nerve growth, but recent findings
suggests a correlation between elevated levels of NGF in the lung and airway
inflammatory diseases. Patients suffering from airway diseases, such as severe asthma,
allergic rhinitis, lung cancer, and respiratory virus infections, have an elevated level of
NGF in both the lung, as determined by bronchoalveolar lavage (BAL) fluid, and blood
(1, 32, 65, 74). In the lungs, NGF can be produced by non-neuronal structural and nonstructural cells. These non-neuronal cells express both the high affinity, trkA, and low
affinity, p75NTR, receptors allowing them to respond to NGF (59, 60). Elevated levels of
NGF in the lung and blood are associated with bronchial hyperresponsiveness and
inflammation in both humans and animals (21, 23, 42, 43). These findings suggest that
the overexpression of NGF in the lung contributes to airway disease progression (16, 17,
20).
Lung function is controlled and regulated through several different cells types,
including airway epithelial cells, airway smooth muscle cells, nerve cells, the pulmonary
vasculature, and inflammatory cells. Although other neurotrophins, such as BDNF, NT-3,
and NT-4/5, and their receptors, trkB and trkC, have also been shown to be elevated
during lung disease, this chapter will focus on previous findings regarding NGF-mediated
mechanisms that have been demonstrated to alter cellular processes to promote disease
progression.

Sources of NGF in the lung
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As mentioned above, there is a correlation between respiratory disease and
elevated NGF levels in patients’ BAL fluid as well as blood. NGF can be produced by
and act upon all cells of the airways. NGF has been shown to be produced by and act
upon structural cells of the airways, including nerves, epithelial cells, fibroblasts, and
smooth muscle cells, and the non-structural cells, such as inflammatory T and B
lymphocytes, mast cells, eosinophils, and macrophages (11, 14, 18, 38, 47, 61, 67, 70).
These airway cells produce more NGF during airway disease conditions to result in
increased concentrations of NGF in the lung and blood. The pro-inflammatory cytokines
TNF-α and IL-1β activate c-fos and c-jun signaling pathways in structural cells of the
airways. The activation of this pathway results in the transcription of the NGF gene, and
results in enhanced NGF expression (19, 22, 28, 39, 47, 48, 53, 54). NGF expression is
elevated in non-structural cells, such as eosinophils in the lung and monocytes in the
blood, in diseases such as asthma (44, 64). NGF also acts as a chemoattractant, which
causes inflammatory cells to migrate into the lung. Enhanced NGF production by several
different cell types of the lung, as well as the increased number of inflammatory cells in
the lung associated with lung diseases, would suggest a correlation between NGF levels
and pathophysiological alterations observed in lung disease.

NGF and airway epithelial cells
The epithelial cells of the airways have several functions including being the
primary barrier against inhaled agents, regulating the airway surface liquid (ASL) levels
through ion transport, and mediating airway smooth muscle tone through the release of
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factors such as epithelium-derived relaxing factor (EDRF)(13). Epithelial cells have been
shown to produce NGF and express the NGF receptors, trkA and p75NTR. Airway
epithelial cells, treated with the pro-inflammatory cytokines TNF-α, IL-1β, and TH2
cytokines, produce and secrete more NGF as compared to non-treated cells (14, 23).
Immunohistochemistry studies of human nasal mucosa has revealed that trkA and p75NTR
receptors are polarized in their locations, with trkA located on the apical membrane and
p75NTR located on the basolateral membrane (75). Elevated levels of NGF in the lung
may function to support the survival of epithelia cells, through trkA-mediated pathways,
as well as promote lung repair (49, 68). Mice which are genetically engineered to
overexpress NGF have subepithelial thickening, which could contribute to airway
remodeling, which is seen in asthmatic patients with advanced disease (30).
The influence of NGF on ion transport in airway epithelial is the focus of the
work presented in this dissertation. Because airway epithelial cells can produce and
respond to NGF, it is possible that NGF could alter ion transport in these cells. The
affects of NGF on ion transport in other cell types will be reviewed later in Chapter three.

NGF and immune cells
Inflammatory cells, such as T and B lymphocytes, mast cells, eosinophils, and
basophils, are elevated in the lungs of patients suffering from respiratory diseases, such
as respiratory virus infections and asthma (25). Elevated levels of neurotrophins,
specifically NGF, are reported in BAL fluid and plasma in patients with asthma, allergic
rhinitis, and respiratory virus infections (55, 63, 74). Inflammatory cells, when stimulated
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with an allergen trigger, produce and secret NGF, resulting in elevated NGF levels in the
lung and plasma (2, 42, 43). Mast cells release NGF upon IgE cross-linking. Eosinophils
produce NGF when treated with NGF or granulocyte-macrophage colony-stimulating
factor (GM-CSF), as well, neurotrophin receptor expression is also increased (35, 44, 56,
72). Macrophages, dendritic cells, and T and B lymphocytes produce elevated levels of
NGF after an antigen challenge (29, 34, 37, 45, 46). Splenic mononuclear cells from
allergen-sensitized mice, which also produce elevated levels of NGF, respond to NGF by
secreting IL-4 and IL-5.
NGF has also been shown to enhance eosinophil survival, increase its cytotoxic
activity, and result in the expression of CD69 on the cell surface (24, 41). NGF also
serves as a chemoattractant for mast cells. NGF, acting through the trkA receptor,
activates the MAPK and PI-3 kinase pathway in mast cells promoting migration (66). The
ability of structural cells of the airways, such as epithelial cells, to produce NGF and
attract inflammatory cells to the lung is a vicious cycle. NGF increases the survival and
function of infiltrating inflammatory cells, which, in turn, will enhance NGF production
and release by inflammatory cells. This excessive NGF production is manifested in
patients’ BAL fluid and blood.

NGF and airway innervation
The first publication that suggested that NGF was involved in mediating airway
hyperresponsiveness (AHR) was that of Hoyle et al. in 1998 (30). At the time, the focus
of this study was not to investigate NGF’s involvement in AHR, but, rather, to investigate
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the role of the sensory nerve mediator, substance P (SP), in the development of AHR.
Hoyle et al. generated a transgenic mouse model in which NGF was overexpressed,
specifically in Clara cells of the lung, by inserting the NGF gene after the Clara-cell
secretory protein (CCSP) promoter. The increased level of NGF produced resulted in
increased innervation of the lung. Mice were treated with 6-hydroxydopamine (6-OHDA)
from the time of birth to inhibit the growth of the sympathetic nerves in the airways, but
6-OHDA allowed enhanced sensory nerve innervation to occur. Sensory nerves in mice
overexpressing NGF demonstrated increased SP expression. These mice displayed AHR
to inhaled capsaicin, which stimulates sensory nerves to release tachykinins. These
findings suggests that elevated levels of NGF in the lung could result in neuronal
remodeling of the lung, as well as regulate sensory nerve SP expression and release
resulting in AHR.
Since the reports above, several other studies have been conducted to investigate
the involvement of NGF in the etiology of AHR. Guinea pigs, injected intravenously with
NGF, developed AHR to histamine after 30 min and 3 h, but AHR was not observed 24 h
post-administration. The AHR could to be blocked with a neurokinin-1 receptor
antagonist, suggesting that NGF can quickly affect sensory nerves to elevate tachykinin
release and cause AHR (9). Tracheal instillation of NGF was also shown to cause
increased production of SP by sensory nerves (73). Although SP’s ability to initiate AHR
was shown to be antagonized by the neurokinin-1 receptor antagonist, SR 140333,
electric field stimulation (EFS) of mouse tracheal segments, treated with the anti-NGFantibody, demonstrated a reduction in reactivity to EFS (2). These reports suggest that
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NGF has multiple effects on the nerves of the airways and could stimulate SP production
in sensory neurons, enhance the sensitivity of sensory nerves to stimuli, such as EFS, and,
as its name implies, enhance nerve growth causing neuronal remodeling of the lung, all of
which would result in AHR observed in patients suffering from lung diseases in which
NGF is overexpressed.

NGF and airway smooth muscle
There has long been an association between airway smooth muscle (ASM) and
airway disease, specifically asthma (51). The amount of ASM present in asthmatics is
increased significantly as compared to non-asthmatics, and this increase in ASM is a
result of cellular hypertrophy and hyperplasia (7). ASM has been shown to produce NGF
and express the trkA, but not p75NTR, indicating that ASM is capable of responding to
NGF (59). The production of NGF by the ASM is increased in the presence of IL-1β and
INF-γ (33). In human airway smooth muscle cells in culture, NGF increased cell
proliferation through a trkA-PKC-p38- and a trkA-ras/raf-Erk1/2-mediated pathway,
indicating that NGF may facilitate airway remodeling of ASM like that observed in
asthmatics (15).

NGF and pulmonary vasculature
The lungs, which are highly vascularized, support gas exchange to maintain a
proper blood oxygen level. Asthma, chronic obstructive pulmonary disease (COPD), and
bronchiectasis are associated with increased vascularization of the bronchial wall (31).
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The remodeling of the pulmonary vasculature, through angiogenesis, is prominent in
patients who die of asthma and contributes to airway disease pathogenesis, specifically
vascular dilation, congestion, and edema, to promote swelling and stiffness of the airway
walls (8, 31). The vascular endothelium produce and respond to NGF through the NGF
receptors, trkA and p75NTR, and the responses to NGF have been shown to be involved in
mediating vascular remodeling associated with airway disease progression (5).
Raychaudhuri et al. reported that NGF could promote endothelial cell
proliferation and up-regulate the expression of intercellular adhesion molecule 1 (ICAM1), a cell surface protein which promotes binding and transmigration of inflammatory
cells, in human dermal microvasculature endothelial cells (58). These findings were
confirmed in several other types of endothelial cells, including human umbilical vein
endothelial cells, (5), human choroidal endothelial cells (69), and rat brain endothelial
cells (40). The expression of ICAM-1 could result in enhanced infiltration of
inflammatory cells into the lung.
NGF produced by structural and non-structural cells in the lung could play a role
in the remodeling of the pulmonary vasculature. NGF has been shown to be a
chemoattractant for endothelial cells, and results in endothelial cell migration, which
could explain the enhanced vascularization of the airways in asthmatic patients (10, 57).
Endothelial cell proliferation due to angiogenesis stimulated by NGF was determined to
be mediated by a trkA pathway. The activation of the trkA receptor promoted the
expression of vascular endothelial growth factor (VEGF) and activation of VEGFreceptors to promote vascular growth (4, 12, 26).
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Vascular dilation has been reported in fatal asthma, and the excessive leakiness of
these vesicles could contribute to airway narrowing (8). NGF can up-regulate endothelial
cell nitric oxide synthase (eNOS) through a trkA-Akt mediated pathway, which will
generate NO and cause vascular dilation (6).

NGF and lung disease
Asthma is an inflammatory disease of the airways, and is characterized by
infiltration of inflammatory cells into the lungs, airway obstruction, and AHR. Elevated
levels of NGF are reported in asthmatic patients’ BAL fluid and blood as compared to
non-asthmatics. The ability of NGF to stimulate AHR through increased SP production
and enhanced sensory nerve sensitivity to stimuli, to cause subepithelial thickening to
reduce airway elasticity, to act as a chemoattractant, to increase the survival of, and
increase the cytotoxicity of inflammatory cells, and to affect pulmonary vasculature to
cause lung edema, to enhance inflammatory cell migration, and to stimulate angiogenesis,
would suggest that NGF is involved intimately in mediating the pathological changes in
the lung resulting in disease progression.
Respiratory syncytial virus (RSV) and human rhinovirus (HRV) infections have
been shown to increase the expression of NGF in the lungs (50, 71). Exposure to these
virus infections early in life, especially in infants less than one year old, can result in
long-lasting effects on the lung, such as increasing the probability of developing asthma
later in life (27). The lungs undergo development during infancy and it is suspected that a
severe RSV infection could cause airway remodeling to give rise to pre-dispose toward
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an asthmatic condition later in life. NGF is vital in the development of both central and
periphery sensory nerves, and the overexpression of NGF early in life could give rise to
changes in nerve innervation and density, function, and development as well as alter
inflammatory responses and evoke changes in epithelial ion transport.
The first reports that a nerve growth agent existed came from the work conducted
by Bueker et al. in 1947, when he demonstrated that mouse sarcoma tumors, when
transplanted intra-embryonically, became highly invaded with nerves (3). Elevated levels
of NGF and trkA expression are observed in malignant cancer cells patients suffering
from non-small cell lung cancer and small cell lung cancer (62). NGF and trkA have been
reported to be overexpressed in several other types of cancers, including esophageal,
breast, cervix, and skin cancer, but all of these cancers lacked the p75NTR receptor, which
is involved in mediating apoptotic pathways (36). NGF has been shown to increase
cellular growth and prolong survival of cultured human lung adenocarcinoma cells
(A549) through a trkA-Akt mediated pathway. When cells were first treated with the nonspecific tyrosine kinase inhibitor, K-252a, prior to the addition of NGF, cells underwent
apoptosis and died (52). Thus, overexpression of the NGF, as well as the lack of the
p75NTR receptor, may be important factors in the development of several cancers in the
body

.
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NGF and Ion Transport

~ 57 ~

Introduction
The epithelial cells which line the airways serve several important functions, such
as acting as a primary physical barrier between the body and the outside environment and
regulating airway surface liquid (ASL). The ASL level is maintained by ion transport,
and proper ASL height is essential to allow ciliary beating to occur and to move inhaled
particles up the airways for removal. Disruption of the ion transport has been shown to be
associated with several airway diseases.
This chapter will review the ion transport proteins responsible for maintaining the
ASL level, discuss airway diseases in which ion transport is affected, and describe the
findings which support out hypothesis that NGF, which is up-regulated in airway
diseases, can regulate ion transport in the airway epithelium.

Ion transport in airway epithelial cells
Airway epithelial cells traffic proteins responsible for ion transport to either the
apical/luminal membrane or the basolateral/blood membrane. This trafficking results in
polarization. Humans airway epithelial cells are primarily Na+ re-absorbers and Cl¯
secretors (53). On the apical membrane, epithelial cells regulate ASL primarily by Na+
reabsorption through epithelial Na+ channels (ENaC) and Cl¯ secretion through the cystic
fibrosis transmembrane conductance regulator (CFTR), Cl¯ channels 2 and 3 (ClC2 and
ClC3), and Ca2+-dependent Cl¯ channels (CaCC). The basolateral membrane contains the
Na+/K+-ATPase, which is the driving force for Na+ reabsorption, the Na+/H+ exchanger
(NHE), the Na+/K+/2 Cl¯ (NKCC) cotransporter, this HCO3¯/Cl¯ anion exchanger, the

~ 58 ~

basolateral outward rectifying Cl¯ channel (BORC), the basolateral inward rectifying Cl¯
channel (BIRC) and the basolateral CFTR-like Cl¯ channel (BCFTR) (32). Figure 3.1,
from Hollenhorst et al. (32), depicts the locations of these transporters on the cell
surface.
ASL levels are maintained through coordinated ion transport by these ion
transport proteins. Song et al., using cultured human airway epithelial cells, human
trachea obtained from lung transplant patients, and pig tracheas, measured ASL levels
under basal conditions, after treatment with the ENaC inhibitor amiloride, and after
CTFR stimulation with cAMP agonist, forskolin (59). Treatment with either amiloride or
forskolin resulted in increased ASL height, or hydration of the ASL, as compared to nontreated preparations. These results indicate the importance of ion transport, specifically
Na+ and Cl¯ transport, in maintaining ASL height.
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Figure 3.1 – Representative model depicting the location of ion channels in airway
epithelial cells. The epithelial cells, through coordinated ion transport, maintain a
properly hydrated ASL to allow for ciliary beating to occur. Human airway epithelial
cells are primarily Na+ re-absorbers and Cl– secretors. The epithelial Na+ channel (ENaC)
is located on the apical membrane and is considered to be the rate limiting step for Na+
reabsorption. On the basolateral membrane, the Na+/K+-ATPase provides the driving
force for Na+ reabsorption. Cl¯ secretion occurs through several Cl¯ channels on the
apical membrane including the cystic fibrosis transmembrane conductance regulator
(CFTR), Cl¯ channels 2 and 3 (ClC2 and ClC3), and Ca2+-dependent Cl¯ channels
(CaCC). The basolateral membrane contains the Na+/K+-ATPase, the Na+/H+ exchanger
(NHE), the Na+/K+/2 Cl¯ (NKCC) cotransporter, the HCO3¯/Cl¯ anion exchanger, the
basolateral outward rectifying channel (BORC), the basolateral inward rectifying channel
(BIRC) and the basolateral CFTR-like channel (BCFTR). Image used with permission
from Hollenhorst et al. (32).
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Sodium transport
As described in the sections 3.2, human airway epithelium is primarily a Na+ reabsorbing epithelium, and ENaC is the rate-limiting step for Na+ re-absorption. This reabsorption occurs through apical ENaC channels, and the driving force for this reabsorption is the Na+ concentration gradient established by the basolateral Na+/K+ATPase. Canessa et al. demonstrated that the ENaC channel is composed of three
subunits, α, β, and γ, and only when the three subunits are expressed together could the
maximum amiloride-sensitive current be obtained (14).
The maturation and activation of these channels occurs after proteolytic cleavage
at two sites on the α-subunit extracellular domain, and on two sites on the γ-subunit
extracellular domain. Hughey et al. published findings demonstrating that furin, an
endoprotease and a member of the proprotein convertase family, cleaves two sites on the
α-subunit and one site on the γ-subunit to result in ENaC maturation and increased Na+
transport in Chinese hamster ovary (CHO) cells (33, 66). Donaldson et al. demonstrated
that ENaC channel activation is regulated by the serine protease, prostasin, which
functions to cleave the extracellular domain on the γ-subunit (23). When Xenopus oocyte
cells were treated with prostasin there was an 80 % increase in ENaC current. The
findings that ENaC could be activated by a serine protease were confirmed in cultured
human primary nasal epithelial cells. Ussing chamber studies were performed using these
nasal epithelial cells to investigate changes in Isc following treatment with the serine
protease trypsin in the absence or presence of the protease inhibitor, aprotinin. When
cells were treated with aprotinin, Na+ current steadily declined. This Na+ current could be
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restored when cells were treated with, trypsin, but no additional increases in Na+ current
were observed when trypsin was applied to non-aprotinin treated cells. Prostasin has been
shown to be a glycosylphosphatidylinositol-anchored membrane bound protein (17). The
cleavage of the α and γ extracellular subunit domains by furin and prostasin result in
increased open probability of the channel, and, therefore, increased Na+ transport.
Regulation of ENaC activity is important for maintaining ASL hydration to allow
cilia to beat. When Na+ is re-absorbed from the lumen and transported to the basolateral
membrane, water flows down its transepithelial osmotic gradient from the lumen to the
basolateral membrane. In order to regulate ASL, ENaC activity must be regulated.
Myerburg et al. published findings which suggest that the airways produce protease
inhibitors to prevent the cleavage and activation of ENaC (47). Using cultured human
primary airway epithelial cells, Myerburg et al. demonstrated that increased ASL volume
dilutes the inhibitory proteases, allowing furin and prostasin to cleave and activate ENaC
and dehydrate ASL to reduce its height. Once the ASL height is reduced to a certain
level, the inhibitory proteases are no longer diluted, allowing once again ENaC activation
by proteolytic cleavage.
Garcia-Caballero et al., using a proteomic approach, identified the secreted short
palate, lung and nasal epithelial clone (SPLUNC) 1 as being responsible for inactivating
ENaC in human primary bronchial epithelial cells (26). SPLUNC1 is expressed and
secreted by the airway epithelium, submucosal glands, and neutrophils. SPLUNC1
represents 10% of the total protein contained in the ASL (4, 13). Regulation of ENaC by
SPLUNC1 results from its direct binding to ENaC to prevent proteolytic cleavage, not by
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inhibiting the proteases furin and prostasin. This binding was determined to be dependent
on ASL height, with higher ASL height causing the dilution, and therefore, inactivation,
of SPLUNC1.
The basolateral membrane of the airway epithelium contains the Na+/K+-ATPase,
which is the driving force responsible for Na+ re-absorption from the lumen. The Na+/K+ATPase is a heterodimer composed of an α1 and β1 subunit, but there have been four αisoforms and three β-isoforms discovered (57). The α1β1 isoform is the primary isoform
in the airway epithelial cells, but it is also expressed by all of the cells in the body. The
expression of the other α and β subunits is highly tissue specific. The α1 subunit is 1,024
amino acids long, contains 4 transmembrane domains on the NH2-terminal segment, a
large cytoplasmic domain, followed by six transmembrane domains on the COOHterminal segment with both the NH2 and COOH regions residing in the cytoplasm (15,
41, 61). The α-subunit is responsible for the 3:2 exchange of Na+/K+, and contains the
phosphorylation sites necessary to activate the pump (62). The α1-subunit also contains
the binding site for Na+/K+-ATPase inhibitor, ouabain, on the extracellular domain
between transmembrane segments 1 and 2 (41). The β1-subunit, which is much smaller
than the α1-subunit, is composed of 304 amino acids, contains three glycosylation sites,
has one transmembrane domain with the NH2 terminal segment located in the cytoplasm,
and contains six cysteine residues important for forming three disulfide bridges (5, 44).
The β1-subunit is suggested to aid in protein trafficking to the basolateral membrane as
well as playing a role in protein regulation (62).
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The Na+/K+-ATPase (i.e., Na+/K+-pump) generates a transepithelial gradient,
causing Na+ to be re-absorbed from the lumen and pumped out of the cell across the
basolateral membrane (5). The activity of basal Na+/K+-ATPase activity is predicted to be
approximately one-third of the pump’s maximum capacity (58). The amount of Na+
pumped out of the cell is determined by the number of Na+/K+-pumps on the membrane,
the turnover activity of the pump, and changes in the pumps affinity for Na+.
Dopaminergic and β-adrenergic signaling in the airways has been shown to rapidly
enhance Na+ transport and reduce lung edema (3). Dopamine and dopaminergic agonists
that bind to the D1, but not the D2 receptor, activate the PKC signaling pathway which is
responsible for causing the exocytosis of intracellular vesicles, which ultimately increases
the number of Na+/K+-pump molecules in the membrane (51). The β-adrenoceptor
agonist, terbutaline, stimulates Na+ reabsorption by activating the Na+/K+-ATPase
through a cAMP-dependent activation of Cl¯ channels (36). Minakata et al. demonstrated
that β- adrenoceptor agonists induced the gene expression of the α-subunit of ENaC and
the α1-subunit of the Na+/K+-ATPase, which resulted in increased Na+ transport as well as
increased Na+ currents in alveolar type II cells (45).

Chloride transport
Cl¯ channels are important regulators of cell volume, cellular pH, and fluid
transport (35). Epithelial cells of the lung secrete Cl¯ into the lumen of the airways, and
this secretion is mediated by the apical Cl¯ channels cystic fibrosis transmembrane
conductance regulator (CFTR), Cl¯ channels (ClC), and Ca+2-activated ion channels
(CaCCs)(Figure 3.1).
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Riordan et al. identified the CFTR gene on chromosome 7, and found it to be
composed of 6,100 nucleotides which encoded a protein containing 1,480 amino acids
and a mass of 168 kDa (52). The protein structure contained two repeated motifs
composed of six membrane-spanning domains, and each motif contained an ATP
nucleotide-binding domain. These two repeated motifs were linked by a regulatory
domain, which contains several PKA and PKC phosphorylation sites (52). The CFTR
NH2 and COOH segments, the nucleotide-binding domains, and the regulatory domain,
were determined to be located in the cytoplasm (22). Tabcharani et al. demonstrated that
the Cl¯ transport by the CFTR is regulated through channel phosphorylation, and
channels could be activated by cAMP, PKA, or PKC, and inactivation was observed
when the channel was dephosphorylated using alkaline phosphatases and fluoride (63).
The ClC family consists of nine family members, with ClC-2 being expressed in
almost all cell types (65). The ClC-2 has been demonstrated to be located in the apical
membrane of the airway epithelial cells (not shown in Figure 3.1), but its expression is
down-regulated after birth (46). The expression of the ClC-2 is not important in
mediating lung development, and ClC-2 knockout mice demonstrate normal lung
development and function (10). The structure of ClC-2 consists of two identical subunits,
each having of eighteen α-helices, which form a rhombus structure that protrudes out of
the membrane (24). Amino acids from four separate regions on the D, F, and N α-helices,
which contain positively charged amino acids, are brought together to form a common
center which generates the pore complex. The positive charged pore region generates a
favorable environment which stabilizes Cl¯ and allows for Cl¯ diffusion (24). Cuppoletti
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et al. published findings demonstrating that ClC-2 channel activity in cultured human
primary buccal cells and immortalized airway cells could be increased when treated with
arachidonic acid, amidation, and omeprazole, which increased Cl¯ current (20)
The CaCCs are reported in several cell types (35). They are located on the apical
surface of airway epithelial cells, are activated by intercellular Ca2+, and play an
important role maintaining ASL levels in the lung (1, 40, 48). Tarran et al. reported that
CaCCs could be stimulated with UTP to result in increased Cl¯ and fluid secretion, as
indicated by increases in ASL height (64). The activation of the CaCC by UTP is a result
of increased IP3 production and release of intracellular Ca2+ (25).

Ion transport and airway disease
As reviewed in section 3.3, Na+ is re-absorbed from the lumen through ENaC, and
this Na+ transport is driven by the Na+/K+-ATPase. When Na+ is re-absorbed from the
lumen, water follows its osmotic gradient from the lumen to the basolateral membrane
and decreases ASL height. When Na+ transport is inhibited, fluid is retained in the lung
causing pulmonary edema. Hummler et al. demonstrated the importance of ENaC in fluid
clearance by generating an α-ENaC knockout mouse (34). No changes in the morphology
of the lung occurred in the knockout animals, indicating ENaC was not responsible for
lung development. However, all mice died within 40 h after birth due to an inability to
clear lung fluid, which was determined by measuring the lung wet/dry ratio.
Transepithelial potential difference measurements of newborn tracheas also revealed that
these mice lacked epithelial Na+ transport, as they were insensitive to amiloride (34).
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Patients suffering from chronic congestive heart failure, acute myocardial
infarction, and intravascular volume overload suffer from severe hydrostatic pulmonary
edema (68). Saldias et al. demonstrated that increased pulmonary arterial pressure
resulted in increased permeability of fluid and albumin into the lung, and this increased
fluid accumulation was a result of decreased Na+ transport (54). The accumulation of
fluid in the airways results in impaired gas exchange, causing hypoxic conditions.
Hypoxic conditions in the airways reduce Na+ transport as well as reduce ENaC and
Na+/K+-ATPase subunit synthesis (31, 42, 49).
Pseudohypoaldosteronism type 1 (PHA1) and Liddle’s syndrome are genetic
diseases in which alterations to genes encoding the ENaC subunits have been reported.
PHA1 is characterized as a salt-wasting disease and results from impaired ENaC function
due to mutations in the α- and β-subunits. Fluid clearance in the lungs of patients
suffering from PHA1 is impaired, and may cause patients to develop a respiratory distress
syndrome (2, 38, 50). Chang et al. identified two mutations in the α-subunit and one
mutation in the β-subunit responsible for impaired ENaC function. The first mutation
detected was a deletion of two bases in exon 2 of the α-subunit, which results in a frame
shift in the amino acid translation producing an α-subunit with a different amino acid
sequence from 68-144. The second mutation changes codon R508 from CGA to TGA, a
premature stop codon. Both mutations to the α-subunit result in a loss of function in
ENaC. The β-subunit mutation results from a glycine to serine mutation at position 37
(G37S). Expression of the mutant β-subunit with wild type α- and γ-subunits in Xenopus
oocytes resulted in a 60 % reduction in ENaC activity as compared to the wild type (16).
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Transgenic mice generated to model PHA1 die within 50 h after birth, again indicating
the importance of ENaC function (6).
Liddle’s syndrome is characterized by early onset of hypertension, normo- or
hypokalemia, metabolic alkalosis, and repressed renin and aldosterone secretion (11).
The generation of a premature stop codon results the deletion of 45-76 amino acids on the
C terminus of the ENaC β- or γ-subunit and results in a 3-fold increase in Na+ transport
(30, 55). Further investigation revealed that the truncated regions of the β- and γ-subunits
contain a proline-rich domain (PPxY), which interacts with the Nedd-4 ubiquitin ligase to
facilitate the degradation of the ENaC channel (60). Because the mutated ENaC β- and γsubunits can no longer interact with Nedd4, there is an increased expression of ENaC
channels on the membrane, which results in increased Na+ transport.
Patients suffering from cystic fibrosis have impaired Cl¯ transport as a result of a
loss of function mutation in their CFTR gene, with the most common mutation being
F508 (39). This mutation results in the CFTR protein misfolding in the endoplasmic
reticulum, but the misfolded protein is still able to be trafficked to the apical membrane.
Although present on the apical membrane, the CFTR is unable to secret Cl¯ (37, 70). In
addition to a loss of Cl¯ transport, airway epithelial cells containing mutated CFTR
demonstrate an increased Na+ transport as compared to cells from non-cystic fibrosis
patients, indicating that CFTR may also regulate ENaC function (18). The loss of Cl¯
transport combined with an increased Na+ transport result in a depleted periciliary liquid
(PCL) layer. This reduction in PCL causes a loss of cilia-dependent mucus transport, and
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results in a thickening of mucus to form mucus plaques and mucus plugging, which
favors growth of bacteria in the airways (12, 43).

NGF and ion transport
The treatment of rat adrenal pheochromocytoma (PC12) cells with NGF results in
a morphological change from a rounded morphology to cells that are long, fine, highly
branched, and synthesize enzymes and neurotransmitters resembling those of sympathetic
neurons (29). The ability to transform PC12 cells into cells with neuronal properties is a
model to study the nervous system.
Schubert et al., using PC12 cells, published the first report of NGF having an
effect on ion transport in cells, specifically Ca+2 (56). This study aimed to investigate the
mechanism by which NGF treatment resulted in an increased nerve outgrowth and
adhesion. The findings suggested that treatment with NGF, acting through a cAMPmediated pathway, resulted in Ca2+ release from intracellular stores to promote cellular
growth and adhesion (56).
Varon et al. demonstrated that NGF could regulate Na+ transport in chick embryo
sensory ganglia, and that this Na+ transport was essential for regulating cell survival, size,
nitrite outgrowth, and the synthesis of neurotransmitter enzymes (28, 67). Boonstra et al.
demonstrated that NGF could activate the Na+/K+-ATPase through increasing amiloridesensitive Na+ transport in both PC12 cells and chick embryo dorsal root ganglia giving
rise to enhanced cellular growth (7-9).
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NGF has also been shown to elicit genomic responses to alter ion transport.
D’Arcangelo et al. incubated differentiating sympathetic neurons and PC12 cells with
NGF and, using a whole cell patch clamp to measure Na+ current, found that NGF
increased Na+ current, with the maximum current being achieved after three days of
incubation with NGF (21). The increased Na+ current was a result of rapid induction of
the type II/IIA Na+ gene, which was a result of activation of a cAMP-dependent, PKAmediated pathway, and induction of the peripheral nerve-type Na+ channel (PN1) gene
through a PKA-independent pathway (21).
As mentioned in Chapter 2, transgenic mice developed to overexpress NGF in
Clara cells of the lung displayed AHR to inhaled capsaicin. Chuang et al. suggested that
NGF is able to sensitize the vanilloid receptor, VR1, on sensory neurons, resulting in an
increased sensitivity to capsaicin, which acts through this receptor (19). Mice injected
with NGF developed thermal hypersensitivity, as measured using a paw withdrawal
assay, and NGF enhanced proton-evoked and heat-evoked currents in oocytes expressing
VR1, trkA, p75, and 5HT3R-A. Chuang et al. concluded that NGF was able to sensitize
the VR1 channel through a PLC-γ mediated pathway, and that VR1 associates with the
NGF-trkA complex (19). Zhang et al. also demonstrated that NGF signaling through the
trkA receptor can enhance TRPV1 channel activity through a PLC-γ pathway, promoting
insertion of TRPV1 receptors into the plasma membrane through a PI3K-mediated
pathway (71).
NGF has also been found to affect ion transport in renal epithelial cells. Watts et
al., using perfused rat medullary thick ascending limb (MTAL) preparations,
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demonstrated that NGF, acting through an Erk-mediated pathway, inhibits the basolateral
Na+/H+ exchanger and apical HCO3¯ absorption (27, 69).
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Introduction
In view of the substantial evidence linking NGF to several pulmonary diseases as
reviewed in Chapter 3, we propose that NGF has the ability to alter ion transport
properties of airway epithelial cells. Ion transport in airway epithelial cells is the
mechanism by which ASL is regulated (3). As well, ion transport is involved in the
release of epithelium-derived relaxing factor, which induces relaxation of airway smooth
muscle and submucosal blood vessels (1, 4, 7). By affecting fluid balance in the lung,
NGF could contribute to disease progression and severity.
The goal of this project is to determine whether NGF alters ion transport in
airway epithelial cells, and to understand mechanisms by which NGF mediates these
responses. We hypothesize that NGF affects ion transport in epithelial cells. To test our
hypothesis, two specific aims have been developed.

Research design and methods
Specific Aim 1: To investigate the effect of NGF on ion transport in human
airway epithelial cells.
Goal: To determine whether NGF alters ion transport in airway epithelial cells,
and to understand how NGF initiates these responses.
Rationale: Because NGF has been shown to facilitate the rapid insertion of ion
channels into the membrane of HEK 293 cells (9) and has been shown to alter the
expression of proteins involved in neural signal transduction (2, 6), we propose that NGF
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will elicit bioelectric responses and alter ion transport after incubation with airway
epithelial cells.

1.1 To investigate immediate bioelectric responses to acute additions of NGF.
Normal human primary cultured epithelial cells that demonstrate desirable in situ
morphology and ion transport function will be placed in Ussing chambers, and Isc will be
recorded. NGF concentration-response curves will be generated for the separate addition
of NGF to the apical and basolateral chambers, because the NGF receptors are located on
either the apical (trkA) and basolateral (p75NTR) membranes (8). The concentration of
NGF that elicits the largest bioelectric response will be used to conduct the remaining
experiments.
To investigate the basis of NGF-induced bioelectric responses, specific ion
transport inhibitors will be used, each one added to the appropriate chamber to inhibit the
channel or transporter of interest. Inferences will be made by comparing the transport
blockers’ responses in the presence or absence of NGF. These results will identify the
ionic basis for NGF-induced bioelectric changes.

1.2 To investigate the effect of incubation with NGF on ion transport.
To investigate if incubation with NGF alters ion transport (as opposed to the
“acute” effect, specific aim 1.1), epithelial cells will be incubated with NGF for 24 and
48 hr. At the conclusion of NGF incubation, cells will be placed into an Ussing chamber,
and responses to ion channel blockers will be measured and compared to control cells
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incubated in the absence of NGF at each time point. Differences in responses to the ion
channel blockers will allow us to make inferences as to the ion channels affected after
incubation with NGF, and, using western blot analysis, we will determine if these
changes are due to changes in channel/transporter expression.

Specific Aim 2: To investigate the molecular pathways involved in NGF
signaling related to epithelial ion transport.
Goal: To determine and understand on a molecular level how NGF mediates
alterations in bioelectric responses of airway epithelial cell.
Rationale: The receptors for NGF have been shown to be polarized across the
epithelial cell, and the NGF response may vary depending on the site of exposure. We
will investigate the molecular mechanism by which the NGF-induced bioelectric
response is occurring.

2.1 To investigate the pathways responsible for NGF-induced alterations ion
transport.
The data generated in specific aim 1.1 will provide insight into the receptor
responsible for the acute NGF-induced alteration in ion transport. If NGF stimulates
bioelectric responses when applied apically ion transport studies will be conducted in the
presence of the non-specific tyrosine kinase inhibitor, K-252a, to investigate whether the
trkA receptor is involved in mediating NGFs bioelectric response. If NGF stimulates
bioelectric responses when applied to the basolateral membrane, ion transport studies will
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be conducted in the presence of the p75NTR receptor inhibitor, TAT-Pep5, to investigate
whether the trkA receptor is involved in mediating NGFs bioelectric response. The
results from these experiments will provide insight into the signaling pathway responsible
for NGF-mediated bioelectric responses.

2.2 To investigate intracellular second messengers involved in NGF-induced
signal transduction in human epithelial cells.
The signaling pathways of both p75NTR and trkA have been extensively
investigated (5). Both receptors are responsible for the activation of several intracellular
signaling pathways, and in this specific aim we will investigate the pathways responsible
for the alteration in the bioelectric properties of airway epithelial cells.
To investigate the intracellular signaling pathway(s) involved in early changes in
ion transport (specific aim 2.1), western blot analysis of phosphorylated protein and unphosphorylated protein will be used.
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Chapter 5
Nerve growth factor reduces amiloride-sensitive
Na+ transport in human airway epithelial cells
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Abstract
Nerve growth factor (NGF) is overexpressed in patients with inflammatory lung diseases,
including virus infections. Airway surface liquid (ASL), which is regulated by epithelial cell ion
transport, is essential for normal lung function. No information is available regarding the effect
of NGF on ion transport of airway epithelium. To investigate whether NGF can affect ion
transport, human primary air-interface cultured epithelial cells were placed in Ussing chambers
to obtain transepithelial voltage (-7.1 ± 3.4 mV), short-circuit current (Isc, 5.9 ± 1.0 µA), and
transepithelial resistance (750 Ω∙cm2), and to measure responses to ion transport inhibitors.
Amiloride (apical, 3.5 x 10-5 mol/L) decreased Isc by 55.3%. Apically applied NGF (1 ng/mL)
reduced Isc by 5.3% in 5 min; basolaterally applied NGF had no effect. The response to amiloride
was reduced (41.6%) in the presence of NGF. K-252a (10 nmol/L, apical) did not itself affect
Na+ transport, but it attenuated the NGF-induced reduction in Na+ transport, indicating the
participation of the trkA receptor in the NGF-induced reduction in Na+ transport. PD-98059 (30
µmol/L, apical and basolateral) did not itself affect Na+ transport, but attenuated the NGFinduced reduction in Na+ transport, indicating that trkA activated the Erk 1/2 signaling cascade.
NGF stimulated phosphorylation of Erk 1/2 and the β-subunit of ENaC. K-252a and PD-98059
inhibited these responses. NGF had no effect on Isc in the presence of apical nystatin (50
µmol/L). These results indicate that NGF inhibits Na+ transport through a trkA-Erk 1/2-activated
signaling pathway linked to ENaC phosphorylation.
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Introduction
Nerve growth factor (NGF), the first member of the neurotrophin family discovered by
Levi-Montalcini (Cohen et al. 1954), is involved in the development, growth, and survival of
sympathetic nerves. Although NGF was discovered in the context of nerve growth and function,
it has been shown to be produced by both structural and nonstructural cells in the lung (Hoyle
2003; Frossard et al. 2004). NGF is involved in the development of several airway diseases, such
as asthma, and neurogenic inflammation (Braun et al. 1998; Nassenstein et al. 2006). Elevated
levels of NGF have been shown to cause airway hyperreactivity, enhance the airway
inflammatory response in ovalbumin-sensitized mice, and cause airway remodeling (Braun et al.
1998; Freund and Frossard 2004). Both NGF and its receptors, trkA and p75, are upregulated
during respiratory syncytial virus infections (Hu et al. 2002; Tortorolo et al. 2005). No studies
have been conducted to investigate the effect of NGF on ion transport in airway epithelial cells.
In addition to acting as a physical barrier, the polarized airway epithelial cells maintain
the airway surface liquid (ASL), which is composed of a periciliary liquid layer (PCL) and a
mucus phase. The PCL is necessary for mucociliary clearance of infectious organisms and
inhaled particles (Toczylowska-Maminska and Dolowy 2012). The PCL is maintained by the
coordinated action of many ion channels, pumps, and transporters (Knowles et al. 1984;
Toczylowska-Maminska and Dolowy 2012). Disruption of ion transport can contribute to airway
diseases, such as mucus thickening in cystic fibrosis due to PCL dehydration, lung edema due to
an inhibition of epithelial Na+ channels (ENaC; Chen et al. 2004; Morty et al. 2007; Ji et al.
2009), and interfere with regulatory mechanisms in the airways, such as the release of
epithelium-derived relaxing factor which induces relaxation of airway smooth muscle and
submucosal blood vessels (Prazma et al. 1994; Fedan et al. 2004; Wu et al. 2004).
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There is a large body of evidence supporting the notion that NGF can alter ion transport
in nonpulmonary cells. For example, in PC12 cells, NGF has been demonstrated to increase Na+
current (Pollock et al. 1990), increase Na+/K+-pump activity (Boonstra et al. 1983), induce type
II/IIA Na+ channel gene expression (D’Arcangelo et al. 1993), and induce expression of the
peripheral nerve-Na+ channel gene, PN42 (Toledo-Aral et al. 1995). In the renal medullary thick
ascending limb (MTAL), NGF inhibits the Na+/H+ exchanger 1 (NHE1; Watts and Good 2002).
In view of the substantial evidence linking NGF to pulmonary diseases, as well NGF’s
ability to alter ion transport in PC12 and the MTAL cells, we hypothesized that NGF is involved
in the regulation of ion transport in airway epithelial cells. Our results suggest that NGF
produces a rapid reduction in amiloride-sensitive Na+ transport in human airway epithelial cells,
that is accompanied by phosphorylation of Erk1/2 and the β-subunit of ENaC.
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Methods
Cell Culture
Normal human bronchial epithelial cells (NHBE, CC- 2540S; Lonza, Walkersville, MD)
were cultured according to the manufacturer’s instructions. NHBE cells were seeded and
expanded (<20 doublings) in a T-75 flask supported by bronchial air–liquid interface (B-ALI)
growth media containing the recommended supplements (B-ALI BulletKit, 193514; Lonza).
Cells were grown to 80–90% confluence. Following trypsinization (100 µL/cm2, 5 min, 25°C),
the cells were transferred to semipermeable rat tail collagen (354236; BD Biosciences, San Jose,
CA)-coated polyester transwell inserts (0.4 µm pore size; 0.33 cm2; 3470; Corning, Corning,
NY) at a density of 50,000 cells/well. The cells were cultured using B-ALI growth medium in
both apical and basolateral compartments for approximately 3 days or until the cells became
confluent. Once confluent, the cells were placed under ALI culture conditions, and only
supported by B-ALI differentiation media containing the recommended supplements in the
basolateral compartment. The cells were allowed to grow for 21 days under ALI conditions with
daily media changes. Growth to confluence was monitored by measuring transepithelial
resistance (Rt, EVOM2; World Precision Instruments, Sarasota, FL), and cells were used after 21
days of growth and when Rt was approximately 1000 Ω∙cm2 (Fig. 1).

Cell imaging
Differentiation into a ciliated pseudo-stratified epithelial cell culture was confirmed
through a series of imaging and staining techniques. The membrane inserts were fixed in 10%
buffered formalin, rinsed in Hank’s balanced salt solution (37°C), dehydrated in graded series of
ethanol, cleared in xylene, infiltrated, and embedded in paraffin. Sections (5 µm) were placed on
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microscope slides, and stained with hematoxylin and eosin (H&E). The samples were imaged on
an Olympus IX70 photomicroscope (Shinjuku, Tokyo, Japan). H&E staining revealed the
presence of a pseudo-stratified epithelial cell culture.
Mucus production was confirmed using alcian blue staining. Membrane inserts were
stained apically with a 1% alcian blue solution (3% acetic acid, pH 2.5) for 30 sec. The alcian
blue solution was removed, and cells were imaged on a Zeiss Axiovert 100 microscope
(Oberkochen, Germany) equipped with a Pixera Pro 150ES camera (Santa Clara, CA).
The presence of cilia was confirmed by immunofluorescence from β-tubulin, scanning
electron microscopy (SEM), and transmission electron microscopy (TEM). For β-tubulin
immunofluorescence membrane inserts were washed with PBS, fixed with apically applied
methanol (4°C), and stained using a monoclonal antitubulin-FITC antibody (F2043; SigmaAldrich, St. Louis, MO). β-tubulin was detected using immunofluorescence on a Axiovert 100
microscope equipped with a Pixera Pro 150ES camera. For SEM, the samples were fixed in 4%
paraformaldehyde fixative and postfixed in osmium tetroxide. The cells were dehydrated in an
ethanol series, dried using hexamethyldisalizane as the final solution and coated with
gold/palladium. The samples were imaged on a Hitachi 4800 field emission scanning electron
microscope (Chiyoda, Tokyo). For TEM, the samples were fixed in Karnovsky’s fixative (2.5%
gluteraldehyde, 2.5% paraformaldehyde in 0.1 mol/L sodium cacodylic buffer), postfixed in
osmium tetroxide, mordanted in 1% tannic acid, and stained en bloc in 0.5% uranyl acetate. The
cells were dehydrated in an ethanol series and embedded in Epon, sectioned, and stained with
Reynold’s lead citrate and an aqueous uranyl acetate. The sections were imaged on a JEOL 1220
transmission electron microscope (Peabody, MA).
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Ion transport in cultured epithelial cells
Transwell cell culture inserts were placed into Ussing chambers (Physiologic
Instruments, San Diego, CA). Cells were bathed in modified Krebs-Henseleit solution (MKHS,
113.0 mmol/L NaCl; 4.8 mmol/L KCl; 2.5 mmol/L CaCl2; 1.2 mmol/L KH2PO4; 1.2 mmol/L
MgSO4; 25.0 mmol/L NaHCO3; and 5.7 mmol/L glucose; pH 7.4; 37°C; gassed with 95% O2,
5% CO2) in both apical and basolateral hemi-chambers. Cells were stabilized under open-circuit
conditions before applying a 0 mV voltage-clamp using an automatic voltage/current amplifier
(EVC 4000, World Precision Instruments or VCC MC8; Physiological Instruments). Shortcircuit current (Isc) and Rt were monitored to investigate whether responses to agents were due to
a change in transcellular as opposed to paracellular ion transport. This was done by delivering 5sec long, 1 mV pulses every 55 sec and calculating Rt using Ohm’s law.

Effects of NGF and agents on ion transport
After stabilization of Isc, concentration–response curves for apical and basolateral
additions of NGF (SRP3018, 0.001–100 ng/mL NGF; Sigma-Aldrich) were generated. The
ability of NGF to alter ion transport responses to amiloride (3.5 x 10-5 mol/L), NPPB (10-4
mol/L), and ouabain (10-4 mol/L) were evaluated in the absence or presence of 1 ng/mL NGF. To
investigate whether the NGF receptor, trkA, mediates the effects of NGF on ion transport, cells
were incubated for 30 min with the nonspecific tyrosine kinase inhibitor, K-252a (10 nmol/L,
apical, K1639; Sigma-Aldrich), or DMSO (0.004%). Subsequently, responses to the ion transport
inhibitors were obtained in the absence or presence of NGF. To investigate whether trkA
activates the Erk1/2 signaling pathway during responses to NGF, cells were incubated 60 min
with the Erk1/2-specific inhibitor, PD-98059 (30 µmol/L, apical and basolateral; 9900L, Cell
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Signaling, Danvers, MA) or DMSO (0.06%). Responses to the ion transport inhibitors mentioned
above were obtained in the absence or presence of NGF after 60 min incubation with either PD98059 or DMSO. To investigate whether NGF could alter ion transport after a 24- and 48-h
incubation, cells were incubated apically with MKHS only or MKHS containing 1 ng/mL of
NGF. Responses to known ion transport inhibitors were evaluated to investigate changes in
ion transport. To investigate whether the effects of NGF involved changes in Na+/K+-ATPase
activity, the apical membrane was permeabilized with nystatin (50 µmol/L, N6261; SigmaAldrich) and responses to ouabain generated in the absence or presence of NGF were compared.
Results are expressed as a percent change in baseline Isc. Results obtained in the presence of
nystatin are expressed as a percent change from the Isc value in the presence of nystatin.

NGF stability and concentration after prolonged incubation periods
To investigate the stability of NGF in sterile MKHS (the medium in which cells were
bathed in Ussing chambers), MKHS with or without 1 ng/mL NGF was added apically to
transwell cell culture inserts, lacking or containing cells, and incubated at 37°C for 5 min, 6, 24,
and 48 h. The basolateral chamber contained MKHS only. An enzyme linked immunosorbent
assay (ELISA; ab99986; Abcam, Cambridge, MA) was used to measure the apical NGF
concentration and endogenous release of NGF from epithelial cells. Results were expressed as a
percent change from the initial NGF concentration.

Protein analysis using western blots of NHBE cells incubated with NGF
Cell lysates were prepared from NHBE cells cultured under ALI culture for 21 days.
Cells were treated with K-252a (10 nmol/L, 30 min, apical) or PD-98059 (30 µmol/L, 60 min,
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apical and basolateral) prior to incubation with either MKHS or MKHS containing 1 ng/ml NGF.
Cells were washed with PBS (4°C) and lysed with Pierce RIPA buffer (89901, Thermo Fisher
Scientific, Waltham, MA) containing halt protease inhibitor (78430, Thermo Fisher Scientific), 5
mmol/L EDTA (1960851, Thermo Fisher Scientific), and phosphatase inhibitor cocktail 2
(P5726, Sigma-Aldrich). Cell lysates were sonicated for two rounds of 10-sec pulses, centrifuged
at 14,000 rpm for 5 min, and protein concentrations were determined using a BCA protein assay
(23227, Thermo Fisher Scientific). Samples were denatured in Laemmli sample buffer (1610737, BioRad, Hercules, CA) containing β-mercaptoethanol (M-6250, Sigma-Aldrich) at 95°C.
Proteins were separated on a 4–15% mini-protein TGX Gel (456-1034, BioRad), and transferred
to a nitrocellulose membrane (162-0112, Bio-Rad). Membranes were blocked for 1 h with
Odyssey blocking buffer (927-40000, Li-Cor, Lincoln, NE) before being probed for 1 h with the
primary antibodies for β-ENaC and phosphorylated-β-ENaC (T615)(ab28668 and ab79172,
Abcam, Cambridge, MA), Erk 1/2 and phosphorylated-Erk 1/2 (ab36991 and ab4819, Abcam),
and β-actin (ab8227, Abcam). Membranes were washed three times with TBST-20 (28360,
Thermo Fisher Scientific), incubated with the secondary antibody, IRDye 680LT (926-68021,
Li-Cor) or IRDye 800CW (926-32210, Li-Cor), washed three more times with TBST-20, and
then developed and analyzed on an Odyssey infrared imaging system (9120, Li-Cor) with
software version 3.0.30. Membranes were stripped between incubations with primary antibodies
using OneMinute Advanced Western Blot Stripping Buffer (GM6031, GM Biosciences,
Rockville, MD). Results are expressed as a percent of control.
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Statistical analysis
Statistical comparisons between groups containing multiple donors were performed with
SAS/STAT software (v9.2) for Windows, utilizing the Proc Mixed function to carry out a oneway analysis of variance. Statistical comparisons between groups involving cells from a single
donor were performed with SigmaPlot 11.0 to carry out a one-way analysis of variance.
Differences were considered significant at p < 0.05.
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Results
Airway epithelial cell characteristics
Cells were cultured under ALI conditions for 30 days, and Rt was measured daily (Fig.
1). The cells generated high epithelial resistance similar to that reported previously in NHBE
cultures grown using ALI conditions (Linet al. 2007). The cells reached a maximum Rt on day
30 (1792 ± 87 Ω∙cm2), and averaged an Rt of 1204 ± 66 Ω∙cm2 from day 10 onward.
The NHBE cells grew into a well-differentiated airway epithelium resembling that of in
situ tissue. H&E staining (Fig. 2A) revealed that cells differentiated into a pseudostratified
epithelium with the presence of cilia on the apical membrane. The production of mucus was
confirmed using alcian blue staining (Fig. 2B). The formation of cilia was confirmed using SEM
(Fig. 2C), TEM (Fig. 2D), and immunofluorescence for β-tubulin, a marker for cilia (Fig. 2E).
The TEM imaging revealed the presence of a 9 + 2 doublet in cilia, indicating that the structures
were not microvilli.
After 21 days of ALI culture, cells placed into a Ussing chamber and allowed to
equilibrate under open-circuit conditions displayed a Vt value of -7.1 ± 3.4 mV. Basal Isc was 5.9
± 1.0 µA/cm2 (average of 4 donors). Preliminary NGF concentration–response curves (0.001–
100 ng/mL) were generated to investigate whether NGF could elicit bioelectrical responses in
airway epithelial cells (data not shown). The addition of NGF to the apical membrane resulted in
a reduction in Isc. NGF did not evoke responses at any concentration after being applied
basolaterally. The concentrations used to generate these NGF concentration–response curves are
clinically relevant and reflect levels found in both the blood and BAL-fluid samples of infants
experiencing respiratory infections and after surgery (Tortorolo et al. 2005). Based on the
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concentration–response analysis, 1 ng/mL of NGF applied to the apical membrane was used
routinely for the remaining experiments as this concentration provided the maximum response.

NGF reduces amiloride-sensitive Na+ transport
To investigate the basis of the bioelectric responses to NGF, ion transport inhibitors were
added apically or basolaterally as appropriate, in the absence (Fig. 3A) or presence (Fig. 3B) of 1
ng/mL NGF. The addition of 1 ng/mL NGF to the apical chamber resulted in a 5.3 ± 1.5%
reduction in Isc. In the absence of NGF, amiloride (3.5 x 10-5 mol/L, apical), which inhibits the
ENaC, caused a 55.3 ± 4.6% reduction in Isc, but in the presence of NGF, amiloride reduced the
Isc by 41.6 ± 3.0% (Fig. 4A; P = 0.0127). NGF had no effect on the response to the Cl- channel
inhibitor, NPPB (Fig. 4B; apical, 10-4 mol/L; control 11.9 ± 1.6%, NGF 13.8 ± 1.7%; P = 0.800)
or the Na+/K+-ATPase inhibitor, ouabain (Fig. 4C; basolateral; control 31.9 ± 2.6%, NGF 35.8 ±
2.6%; P = 1.00). The decrease in amiloride-sensitive Na+ transport by NGF was observed in the
epithelium from four different donors (Fig. 5). Because of the consistency of the amiloride
response between donors, it was decided to use the epithelial cells from one donor for the
remaining experiments.
In the above experiments the cells had been incubated with NGF until a stable response
was obtained, that is, ~5 min, before amiloride was applied. To investigate whether the effect of
NGF on Na+ transport was maintained for longer period of time, responses to amiloride were
generated following 30-min incubation with 1 ng/mL NGF. Under these conditions responses to
amiloride were reduced in magnitude in the presence of NGF, albeit not significantly (Fig. 6).

NGF reduces amiloride-sensitive Na+ transport through a trkA receptor-mediated pathway
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To investigate whether the trkA receptor, which has been identified histologically on the apical
surface of airway epithelial cells (Wu et al. 2006), mediates the reduction in amiloride-sensitive
Na+ transport in response to NGF, cells were incubated for 30 min with the nonspecific tyrosine
kinase inhibitor K-252a (10 nmol/L; apical) or DMSO as the vehicle control (0.004%). K-252a
significantly reduced NGF responses (Fig. 7A). K-252a itself did not have an effect on
amiloride-sensitive Isc, but K-252a attenuated the NGF-induced reduction in Na+ transport
(Fig. 7B). There were no significant changes in the responses to NPPB or ouabain, indicating
that there were no changes in Cl- transport or Na+/K+-ATPase activity (Fig. 7C and D). These
results suggest that the trkA receptor mediates bioelectric responses to NGF and its activation
inhibits amiloride-sensitive Na+ transport.

NGF reduces amiloride-sensitive Na+ transport through a trkA/Erk1/2-mediated pathway
The trkA receptor, when activated by NGF, can activate several intracellular signaling
cascades, including the Erk1/2 signaling pathway (Segal and Greenberg 1996). To investigate
whether the NGF-induced reduction in amiloride-sensitive Na+ transport involves the activation
of the Erk1/2 signaling cascade, cells were incubated with either the Erk1/2 inhibitor, PD-98059
(30 µmol/L; apical and basolateral), or DMSO (0.06%) 60 min prior to generating responses to
ion transport inhibitors in the absence or presence of NGF. PD-98059 itself significantly reduced
the response to NGF (Fig. 8A), and also attenuated the NGF-induced reduction in amiloridesensitive Na+ transport (Fig. 8B). Again, there were no significant changes in the responses to
NPPB or ouabain, indicating that there were no changes in Cl- transport or Na+/K+-ATPase
activity (Fig. 8C and D). These findings suggest that Erk1/2 participates in the reduction in
amiloride-sensitive Na+ transport in response to NGF.

~101~

NGF does not affect Na+/K+ ATPase activity
Although apically applied NGF did not result in significant changes in Na+/K+-ATPase
activity (Fig. 4C), Erk 1/2 activation has been reported to affect Na+/K+-ATPase expression
(Guerrero et al. 2001) and activity (Lei et al.2008) in alveolar epithelial cells. It is possible,
therefore, that NGF could affect Na+/K+-ATPase activity in addition to Na+ transport. To
investigate whether NGF affects Na+/K+-ATPase activity, the apical membrane was
permeabilized with nystatin (50 µmol/L; apical), and responses to ouabain were obtained in the
absence (Fig. 9A) or presence (Fig. 9B) of NGF (1 ng/mL). In the presence of nystatin, apically
applied NGF had no effect on Isc, in contrast to responses of cells in the absence of nystatin (data
not shown). There was no significant difference in the responses to ouabain between the vehicle
control and NGF-treated groups (Control 98.4 ± 1.2%, NGF 99.7 ± 0.8%; data not shown).
These results suggest that the NGF-induced Erk 1/2 activation is a localized signaling event
which occurs at the apical membrane that affects amiloride-sensitive Na+ transport but not
basolateral Na+/K+-ATPase activity.

Prolonged incubation with NGF
To examine the effect of prolonged incubation with NGF, cells which were incubated for
24 h (Fig. 10A–C) or 48 h (Fig. 10D–F) with apically applied NGF (1 ng/mL) or MKHS, were
placed into the Ussing system to measure responses to amiloride. NGF did not reduce the
amiloride-sensitive Na+ transport in cells incubated for either 24 or 48 h, which suggested at first
that the reduction in Na+ transport is a transient, nongenomic cellular response to NGF.
We considered the possibility that the lack of a lasting effect of NGF on amiloridesensitive Na+ transport could be due to a reduction in NGF concentration during the incubation
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period or due to desensitization of the cells. Therefore, an ELISA specific for β-NGF was used to
measure the NGF concentration in the apical solution. Transwell inserts with and without cells
were incubated for 5 min, or 6, 24, and 48 h apically with either NGF (1 ng/mL) or MKHS. After
incubation, the apical solution was collected and analyzed for NGF. There were no detectable
levels of endogenous NGF in any of the transwell inserts with or without cells incubated with
MKHS. However, following 5-min incubation on inserts which contained cells, the NGF
concentration was reduced by 93%. Transwell inserts which did not contain cells and were
incubated with NGF did not reveal a reduction in NGF concentration, indicating that NGF was
either metabolized by epithelial proteases or NGF was internalized into the cells with the trkA
receptor, as reported previously (Saragovi et al. 1998).
In the presence of epithelial cells, 94.7 ± 0.4%, 94.9 ± 0.5%, and 96.1 ± 0.1% reductions
in NGF concentration were observed following 6, 24, and 48 h of incubation, respectively. In
inserts lacking cells, which did not reveal a decrease in NGF after 5 min, there were 84.2 ± 2.3%,
99.8 ± 0.1%, and 99.9 ± 0.0% reductions in NGF concentration following a 6-, 24-, and 48-h
incubation, respectively. The reduction of NGF in transwell inserts without cells demonstrates
that NGF is degraded when incubated at 37°C in MKHS for a prolonged period of time.

NGF mediates ENaC phosphorylation through a trkA-Erk 1/2 signaling pathway
In the Ussing system experiments, we demonstrated that NHBE cells respond
electrophysiologically to apically applied NGF, and, in the presence of NGF, amiloride sensitive
Na+ transport was attenuated. Furthermore, K-252a and PD-98059 inhibited NGF’s effect.
Apically permeabilized epithelial cells were unresponsive to NGF, and NGF was found to have
no effect on the Na+/K+-ATPase activity. Epidermal growth factor (EGF) also has been shown to
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activate an Erk 1/2-mediated pathway and selectively inhibit ENaC without affecting Na+/K+ATPase activity (Shen and Cotton 2003). Thus, the ability of NGF to activate the Erk 1/2
signaling, as well as the possibility that NGF, acting through this second messenger pathway,
could phosphorylate ENaC was investigated. Treatment with apical NGF (1 ng/mL, 5 min)
resulted in a twofold Erk 1/2 activation (Fig. 11A) and a threefold increase in β-ENaC
phosphorylation (Fig. 11B) as compared to controls. The increases in Erk 1/2 activity and βENaC phosphorylation were blocked by K-252a (10 nmol/L, apical) and PD-98059 (30 µmol/L,
apical and basolateral; Fig. 11C). Although there was a threefold increase in β-ENaC
phosphorylation, there were no changes in total β-ENaC (Fig. 12). These results could suggest
that NGF, acting though a trkA-Erk 1/2-mediated pathway, causes the phosphorylation of ENaC,
which could be associated with reduced Na+ transport.
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Discussion
The addition of NGF to the apical membrane of NHBE cells decreased Isc, and reduced
amiloride-sensitive Na+ transport. NGF did not affect Cl- transport or Na+/K+-ATPase activity, as
there were no effects on the responses to NPPB or ouabain, and NGF was ineffective in the
presence of nystatin to short circuit the apical membrane. The nonspecific tyrosine kinase
inhibitor, K-252a, as well as the specific Erk 1/2 inhibitor, PD-98059, attenuated both the
response to NGF as well as the NGF-induced reduction in amiloride-sensitive Na+ transport.
NGF did not reduce amiloride-sensitive Na+ transport after a 24- or 48-h incubation, which
appears to be a result of NGF degradation. This finding also implies that NGF did not elicit early
genomic effects to change ion transporter expression under the conditions of our experiments.
The results would suggest that NGF, acting through a trkA-Erk1/2- mediated signaling pathway
leading to ENaC phosphorylation, reduces Na+ transport in airway epithelial cells.
There has been extensive work to investigate the regulatory mechanisms controlling
ENaC, as ENaC not only plays a critical role in airway fluid clearance but also in the kidney
where it is involved in maintaining blood volume and pressure (Bhalla and Hallows 2008). The
regulation of ENaC can be controlled through a variety of both extrinsic and intrinsic factors,
both through genomic effects, such as protein synthesis, and nongenomic effects, such as the
change in the number of ENaC channels expressed on the membrane or a change in ENaC
kinetics. The rapidity of the NGF-induced reduction in Na+ transport would suggest that the
mechanism involves a nongenomic mechanism(s).
The addition of NGF to the apical membrane, but not the basolateral membrane, resulted
in a decrease in Isc. Previous work suggests the specific trafficking of the trkA receptor to the
apical membrane and the p75 receptor to the basolateral membrane (Wu et al. 2006). The lack of
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bioelectric response when NGF was applied to the basolateral membrane, as well as the
significant reduction in the response to apically applied NGF in the presence of K-252a, would
suggest the interaction of NGF with the apical trkA receptor led to altered ion transport.
NGF, specifically protein loops 2 and 4, interacts with the trkA receptor, but not with the
p75 receptor, to phosphorylate and activate the Erk1/2 signaling pathway (Xie et al. 2000). The
interaction between NGF and trkA occurs within 1 min, with maximum trkA activation
occurring after a 5-min incubation with NGF (Kaplan et al. 1991). Activated Erk 1/2 mediates
the phosphorylation of two specific threonine residues on the β- and γ-ENaC subunits located
near a PXTP motif on the cytosolic C-terminus (Shi et al. 2002). The phosphorylation of βThr613 and γThr-623 on ENaC results in much higher binding affinity between the WW domain on
the E3 ubiquitin-protein ligase Nedd4 and the PXTP motif on ENaC, resulting in the
ubiquitination and downregulation of ENaC. Although NGF activates the Erk1/2 signaling
pathway downstream of the trkA receptor and activated Erk1/2 has been shown to phosphorylate
and downregulate ENaC, no previous study has investigated NGF’s ability to activate the Erk1/2
signaling pathway and the resulting phosphorylation of ENaC in airway epithelial cells.
The ELISA data demonstrated a rapid reduction (93% in 5 min) in apically applied NGF
in the presence of epithelial cells. Without NGF present in the apical bath continued signal
activation would not be expected to occur. However, NGF has been shown to cause trkA
activation in 1 min (Kaplan et al. 1991) and maximum Erk activation 1.5 min after exposure
(Saragovi et al. 1998). This rapid signaling coincides with the rapid electrophysiological
responses stimulated by NGF. Thus, the bioelectric and the biochemical events would appear to
have followed a similar time course. After 30-min incubation with NGF, at a time when NGF
concentration in the chamber had diminished substantially, the effect of amiloride was blunted

~106~

and was no longer significant. This must reflect the decline in NGF levels during this period. But
the fact that there was a trend toward an effect on responses to amiloride could suggest,
interestingly, that NGF had initiated a longer term, “hit and run” effect during the first 5 min of
incubation.
Although we observed a threefold increase in β-ENaC phosphorylation after a 5-min
incubation with NGF, we did not observe a reduction in total β-ENaC (Fig. 12) over the
measurement period. Falin and Cotton (2007) using MDCK cells demonstrated that EGF induced
an Erk-mediated reduction in Na+ transport as a result of ENaC phosphorylation, but a reduction
in ENaC surface expression was not observed until after 60 min. It is possible that longer
incubations with NGF (under conditions in which NGF levels might somehow be stabilized in
MKHS) could reveal ENaC degradation late in the response. During diseases such RSV
infections, NGF is significantly increased in the cell fraction of the bronchoalveolar lavage fluid,
but not in the serum (Tortorolo et al. 2005). This increased NGF level has been attributed to
increased production by the infiltrating inflammatory cells. The increased production and release
of NGF by inflammatory cells would result in a continuous release of NGF and exposure of the
epithelium, and, perhaps, initiate changes in ion transport by mechanisms uncovered during this
investigation.
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Figure 1. Time course of the development of Rt in air–liquid interface (ALI)-cultured normal
human bronchial epithelial cells (NHBE). Rt was monitored over 30 days on ALI. NHBE cells
generated and maintained high resistance after 10 days on ALI culture (n = 1 donor, 12
replicates).
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Figure 2. Confirmation of normal human bronchial epithelial cell (NHBE) differentiation. The
differentiation of NHBE cells was confirmed through several imaging techniques. (A)
Hematoxylin and eosin staining revealed a pseudo-stratified epithelium with the presence of
cilia, (B) alcian blue staining confirmed mucus production, and (C) scanning electron
microscopy revealed the presence of cilia on the apical surface. These structures were confirmed
to be cilia through the use of (D) transmission electron microscopy, which revealed the presence
of a 9 + 2 doublet of microtubules, and (E) immunofluorescence for β-tubulin.
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Figure 3. Representative Isc tracings of responses to known ion transport inhibitors. Once Isc
stabilized, responses to amiloride (3.5 x 10-5 mol/L), NPPB (10-4 mol/L), and ouabain (10-4
mol/L) were generated in the (A) absence or (B) presence of 1 ng/mL nerve growth factor
(NGF).
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Figure 4. Effect of nerve growth factor (NGF) on ion transport. Responses to (A) amiloride, (B)
NPPB, and (C) ouabain were calculated as percent change from baseline (4 donors). NGF
significantly reduced the amiloride response (P = 0.0127).
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Figure 5. Effect of nerve growth factor (NGF) on amiloride-sensitive Na+ transport. Normal
human bronchial epithelial cells cultured from four donors demonstrated consistent reductions in
Na+ transport in the presence of 1 ng/mL NGF.
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Figure 6. Effect of nerve growth factor (NGF) on responses to apically applied amiloride after
30 min. Although the response to amiloride was reduced in the presence of NGF, this reduction
was not significant. n = 4.
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Figure 7. Effect of nerve growth factor (NGF)-induced trkA activation on amiloride-sensitive
Na+ transport. Cells were either incubated apically with the nonspecific tyrosine kinase inhibitor,
K-252a, or DMSO for 30 min prior to generating responses to (A) NGF, (B) amiloride, (C)
NPPB, and (D) ouabain in the absence or presence of NGF. Incubation with K-252a significantly
attenuated both the (A) NGF response (P = 0.04) and (B) the NGF induced reduction in
amiloride-sensitive Na+ (*P = 0.002; #P = 0.041). DMSO n = 4; all other groups n = 6.
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Figure 8. The involvement of the trkA downstream signaling pathway, Erk 1/2, in the nerve
growth factor (NGF)-induced reduction in amiloride-sensitive Na+ transport. Cells were either
incubated apically and basolaterally with the specific Erk 1/2 inhibitor, PD-98059, or DMSO for
30 min prior to generating responses to (A) NGF, (B) amiloride, (C) NPPB, and (D) ouabain in
the absence or presence of NGF. Incubation with PD-98059 significantly attenuated both the (A)
NGF response (P = 0.001) and (B) the NGF induced reduction in amiloride-sensitive Na+
transport (*P = 0.002; #P = 0.012). DMSO n = 4; all other groups n = 6.
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Figure 9. The effect of nerve growth factor (NGF) in epithelial cells permeabilized apically with
nystatin. Cells were placed into Ussing chambers and allowed to equilibrate prior to adding
nystatin (50 lmol/L) to the apical chamber. Nystatin caused a large increase in Isc. Responses to
ouabain were generated in the (A) absence (vehicle control – modified Krebs-Henseleit solution
[MKHS]) or (B) presence of 1 ng/mL NGF. NGF did not elicit bioelectric responses when
applied apically to the permeabilized cells, and did not alter Na+/K+-ATPase activity as there
were no differences in the response to ouabain. Control n = 6, NGF n = 4. Scale bar = 10 min.
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Figure 10. Effect of prolonged incubation with nerve growth factor (NGF) on ion transport.
Responses to known ion transport inhibitors were generated after incubating cells 24 h (A–C)
and 48 h (D–F) with 1 ng/mL NGF. There were no difference in response to amiloride (A and
D), NPPB (B and E), and ouabain (C and F) between control or NGF treated cells following
either a 24- or 48-h incubation (2 donors).
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Figure 11. Western blots showing the effects of nerve growth factor (NGF) on Erk 1/2 activation
and ENaC phosphorylation. Cells were incubated apically with modified Krebs-Henseleit
solution (MKHS; control) or 1 ng/ml NGF in MKHS for 5 min. (A) NGF activated the Erk 1/2
signaling pathway. This activation was inhibited by K-252a and PD-98059. (B) NGF-mediated
activation of Erk 1/2 resulted in ENaC phosphorylation, and was inhibited with K-252a and PD98059. (C) Representative blots for Erk 1/2 (42 and 44 kDa), phosphorylated Erk 1/2 (P-Erk; 44
and 45 kDa), phosphorylated ENaC (76 kDa), and the loading control, β-actin (47 kDa). n = 4.
*P < 0.05.
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Figure 12. Western blots showing the effect of nerve growth factor (NGF) on β-ENaC. (A and
C) Cells incubated with NGF for 5 min demonstrated a threefold increase in phosphorylated-βENaC (76 kDa). (B) Blots were stripped and probed for β-ENaC (75 kDa) and β-Actin
(42 kDa). NGF did not affect β-ENaC levels. n = 6, *P < 0.05.
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Chapter 6
Summary and Conclusion
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The work presented in this dissertation demonstrates that NGF, acting through a
trkA-Erk 1/2 mediated pathway, reduces amiloride-sensitive Na+ transport in NHBE
cells. The reduction of Na+ transport in airway epithelial cells would result in periciliary
liquid (PCL) hydration, which could lead or contribute to pulmonary edema. Although
this project has identified the initial observation that NGF can regulate Na+ transport in
the airway epithelium, there are still several questions left unanswered, but the work
presented has laid the foundation for several subsequent experiments.

Specific Aim 1: To investigate the effect of NGF on ion transport in human
airway epithelial cells.
The goal of specific aim 1 was to identify if NGF can elicit bioelectric responses
in NHBE cells, and understand how NGF is mediating these responses. To first identify
whether NGF has a bioelectric effects on the airway epithelium, both the apical and the
basolateral membrane NGF concentration-response curves were required.
Immunohistological reports identified the trkA receptor to be located to the apical
membrane and the p75NTR receptor to be located on the basolateral membrane. NHBE
cells responded with changes in Isc only after NGF was applied to the apical, but not the
basolateral membrane. This would suggest that either the trkA receptor is responsible for
mediating the bioelectric responses, or that NGF was having an effect on directly on ion
transport channels.
To investigate the molecular basis for the NGF bioelectric response, specific ion
transport inhibitors were used, and differences in response to these inhibitors were
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measured. In the presence of NGF, the amiloride response, or Na+ transport, was reduced,
but there were no differences in the response to NPPB or ouabain, indicating that Cl¯
transport or Na+/K+-ATPase were unaffected by NGF. The mechanism by which NGF
was able to reduce the amiloride-sensitive Na+ transport was further investigated in
specific aim 2.
To investigate whether NGF could induce lasting changes in NHBE cells, cells
were incubated for 24 or 48 h with NGF, and responses to known ion channel inhibitors
were obtained. There were no differences in the responses to the channel inhibitors,
indicating NGF did not initiate genomic effects to alter channel subunit expression during
the period of incubation. The stability of NGF in culture was investigated to determine if
this lack of effect was related to a degradation of NGF. To evaluate this possibility, the
NGF concentration was measured after a 5 min, 6, 24, and 48 h incubation. Within 5 min,
the NGF concentration was reduced by 93.4 % from the initial concentration applied to
the cells. There were no detectable changes in the NGF concentration after 5 min when
transwell inserts without cells were incubated with NGF. This indicates that the observed
reduction in NGF concentration was a result of either NGF being metabolized or
internalized by the epithelial cells. Rapid internalization has been documented using
radiolabeled NGF (3). There were no measurable differences in channel blocker
responses 24 or 48 h following a single application of NGF, indicating there were no
changes in channel expression and that channel subunit protein expression studies were
not warranted.
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Specific Aim 2: To investigate the molecular pathways involved in NGFsignaling related to epithelial ion transport.
The goal of specific aim 2 was to investigate and determine the molecular
pathway NGF is activating to reduce Na+ transport. Based on the initial finding that NGF
elicits a bioelectric effect when applied to the apical but not the basolateral membrane,
we investigated whether NGF signaling through the trkA receptor caused a reduction in
amiloride-sensitive Na+ transport. This was accomplished by incubating cells with the
non-specific tyrosine kinase inhibitor K-252a prior to the addition of NGF. K-252a
reduced the response to NGF and attenuated NGF’s effects on amiloride-sensitive Na+
transport, indicating trkA’s involvement in the NGF-induced reduction in Na+ transport.
The Erk 1/2 signaling pathway has been shown to be activated by the trkA
receptor, and EGF-activated Erk 1/2 signaling has been shown to reduce Na+ transport in
renal epithelial cells by phosphorylating ENaC to promote its internalization and
degradation through a NEDD4 pathway. To investigate whether NGF was also acting
through an Erk 1/2 mediated pathway to reduce Na+ transport, cells were incubated with
the specific Erk inhibitor PD-98059. The treatment with PD-98059 reduced the response
to NGF and attenuated NGF’s effect on amiloride-sensitive Na+ transport.
To obtain additional evidence that NGF was activating Erk 1/2, and, that ENaC
was being phosphorylated, cells were incubated with NGF for 5 min and Erk activation
and ENaC phosphorylation were investigated. NGF caused an increase in Erk 1/2
activation and ENaC phosphorylation, both of which were blocked by either K-252a.
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These results have demonstrated that NGF, acting through the trkA receptor,
activates the Erk 1/2 signaling pathway, which in turn phosphorylates ENaC.
Phosphorylated ENaC has a higher affinity for NEDD4, and is ubiquitinated, internalized,
and degraded. The reduction in ENaC on the apical membrane results in a reduced Na+
transport. This reduction is transient, as the cells do not display reductions in Na+
transport 24 and 48 h post-exposure.

Future experiments
Although the data presented in this dissertation identified the initial observation
that NGF is able to regulate Na+ transport in the airway epithelium, there are still several
unanswered questions requiring investigation.

NGF’s effect on ASL height
In NHBE cells, NGF produced a 14 % reduction in amiloride-sensitive Na+
transport. The physiological significance of this reduction needs to be addressed.
Confocal microscopy techniques have been developed to study changes in ASL height,
with optimal PCL found to be approximately 7 µm, the length of extended cilia (1). To
identify the effect NGF has on fluid clearance in the lung, laser scanning confocal
microscopy can be used to study changes in ASL in response to agents and channel
inhibitors, as previously reported (4). To study changes in ASL, epithelial cells will be
stained with Cell Track Green and the ASL will be stained with rhodamine B-dextran.
Cells will be exposed to either MKHS or MKHS containing NGF, and changes in ASL
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will be monitored over a period of time to investigate ASL height. Responses to ion
transport inhibitors can be used to cause changes in ASL height through the activation or
inhibition of ion transport. These responses will be generated in the absence or presence
of NGF, and ASL height will be monitored. It is expected, since NGF reduces Na+
transport, that cells treated with NGF will have a higher ASL than cells treated with
control media.

NGF’s effects on alveolar type II cells
The cells used to conduct the experiments outlined in this dissertation were
bronchial/tracheal epithelial cells, but alveolar type II (ATII) cells are considered to be
the primary site for airway fluid removal in the lung. To confirm that NGF reduces Na+
transport in airway epithelium, the experiments in this dissertation should be duplicated
using ATII cells isolated from rodent lungs or purchased commercially. The human
primary NHBE cells used in this dissertation were purchased from Lonza, and Lonza also
has human primary small airway epithelial cells (SAEC)(CC-2547) available. Although
the cells purchased from Lonza are a mixture of several different cell types from the
lower airways, these cells do contain ATII cells. A description of the percentage of ATII
cells in each culture population is not available from the company at this time, but cell
specific staining could be performed to determine cell culture populations. The company
also manufactures specific medium which allows SAEC to be cultured on ALI, and
cellular differentiation into cells representing in situ epithelial cell morphology can be
generated. These cells also generate an electrical resistance of 814±55 Ω∙cm2. These cells
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would be an excellent model to investigate ion transport using similar electrophysiology
techniques described in this dissertation and also used in measuring ASL height, as
covered in 6.3.1.

Desensitization to NGF
Kaplan et al. reported that NGF stimulated the trkA receptor in PC12 cells after a
1 min and reached a maximum activation after a 5 min incubation (2). Once bound, the
NGF-trkA complex has been shown to be internalized (3). We demonstrated that NHBE
cells rapidly reduced the concentration of apically applied NGF within 5 min,
corroborating these previous reports of a rapid activation and internalization of the NGFtrkA complex. The reduction of NGF receptors on the cell surface due to receptor
internalization would result in a cellular desensitization to NGF, but the ability for cells
to become desensitized to NGF warrants further investigation.
To investigate NGF mediated trkA internalization, florescent studies to monitor
trkA internalization will be conducted as previously reported (5). Cultured human
epithelial cells will be treated apically NGF before being fixed, permeabilized, and
stained for activated trkA.
As previously mentioned, histological evaluation of nasal mucosal demonstrated
the specific targeting of trkA to the apical membrane and p75NTR to the basolateral
membrane. These additional fluorescent studies would also confirm the specific
membrane trafficking of the trkA and p75NTR receptor in our cultured airway epithelial
model.
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Although a single exposure of NGF did not result in genomic changes and the
concentration of a single addition of NGF was reduced 93.4 % within 5 min, this
exposure does not represent the physiological conditions epithelial cells are exposed to
during lung disease in which NGF is continuously being secreted. Cells will be treated
repeatedly at intervals during the 24 or 48 h incubation period to better simulate the
physiological conditions of the lung during disease in which epithelial cells are constantly
exposed to elevated levels of NGF. Ion transport in these cells would then investigated
using similar electrophysiological experiments as mentioned previously.
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